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Abstract
Ischemia/reperfusion injury (IRI) is inherent to renal transplantation (RTx) and is
initiated when blood supply is necessarily removed during organ procurement (ischemia)
and subsequently restored upon engraftment (reperfusion). During renal ischemia, ATP
depletion causes tubular epithelial cell (TEC) injury and subsequent release of proinflammatory mediators. Upon reperfusion, influx of O2 causes reactive oxygen species
(ROS) production and infiltration of innate immune cells which release damaging ROS
and proteases. Prolonged periods of IRI are associated with increased risk of delayed
graft function (DGF) and decreased long-term graft survival. The endogenously produced
gasotransmitter, hydrogen sulfide (H2S), has recently been shown to mediate
cytoprotection against ischemic tissue injury. Our investigation examines whether
addition of H2S to standard organ preservation solution can better mitigate IRI associated
with prolonged cold storage. We have demonstrated that addition of H2S to University of
Wisconsin (UW) preservation solution significantly improves early graft function and
survival following both moderate (6-hour) and prolonged (24-hour) cold storage during
syngeneic (genetically identical) and allogeneic (genetically dissimilar) murine RTx. H2S
treatment significantly reduced acute expression of renal injury markers compared to
UW, but did not alter progression of allograft rejection. Targeting H2S release to
mitochondria improved the potency of H2S-mediated renoprotection >1000 fold during
both in vitro and in vivo cold hypoxic/ischemic injury. Our studies provide a strong base
of evidence that H2S treatment improves the protective capacity of standard organ
preservation solution during both moderate and prolonged cold storage and could
diminish the detrimental outcomes of prolonged cold IRI during clinical RTx.
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Chapter 1

1

Introduction

Overview: This introductory chapter illustrates the increasing need for renal
transplantation, discusses current challenges facing its implementation and success, and
outlines potential novel therapeutic strategies to improve clinical outcomes for renal
transplant patients.

Citation:
Lobb I, Sonke E, Aboalsamh G and Sener A. Hydrogen sulfide and the kidney: important
roles in renal physiology and pathogenesis and treatment of kidney injury and disease.
Nitric Oxide-Biol Ch, 2015 Apr;46:55-65. Elsevier B.V. ©.
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1.1 End-Stage Renal Disease
End-stage renal disease (ESRD) is the final stage of chronic kidney disease (CKD) during
which the kidneys no longer function at the level necessary to sustain the life of an
individual 1. In developed countries, ESRD is primarily caused by progressive kidney
injury associated with chronic diseases such as Type 2 diabetes mellitus and hypertension
as well as glomerulonephritis and cystic kidney disease 2,3. In the past 20 years, the
prevalence of ESRD has more than doubled in North America, to over 1100 patients per
million in Canada and over 1900 patients per million in the United States, and incidence
of ESRD continues to rise in accordance with increasing rates of Type 2 diabetes and
hypertension 2,3. Thus, ESRD represents a major burden to the healthcare system both
currently and in the future.
Patients with ESRD exhibit an estimated glomerular filtration rate (eGFR) of less than 15
mL/min (per 1.73 m2 body surface area) and require renal replacement therapy (RRT) for
survival 1. Two forms of RRT are currently available for treatment of renal failure in
ESRD patients: dialysis and renal transplantation. Dialysis is a therapeutic intervention in
which metabolic waste products are removed from the circulation either by direct
filtering of blood (hemodialysis) or passive diffusion of solutes across the peritoneal
membrane upon infusion of dilute solution (peritoneal dialysis) 4. Dialysis is an effective
method of acutely replacing renal function and, considering its ease of access, is the firstline treatment for ESRD patients. However, chronic use of dialysis is associated with
increased rates of infection and cardiovascular complications and is not the ideal
treatment modality for long-term management of ESRD patients 4. The alternative to
dialysis for treatment of ESRD is renal transplantation, which involves the procurement
of a kidney from a donor patient and subsequent engraftment into a recipient patient.
Upon transplantation, the donor kidney is able to function at the level required to
sufficiently remove metabolic waste products from circulation and sustain the life of the
patient without need for continued dialysis. Renal transplantation provides a more
effective method of replacing renal function and is associated with fewer cardiovascular
complications compared to dialysis 5. Accordingly, Canadian ESRD patients who receive
renal transplantation exhibit a 5-year graft survival rate of 89.2% for living donors and
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82.6% for deceased donors, compared to only 44.8% survival for ESRD patients
receiving dialysis alone 3. As well, due to the elimination of either multiple visits per
week to dialysis clinics for hemodialysis or frequent dialysis sessions via a permanent
peritoneal catheter, ESRD patients who receive renal transplantation report greatly
improved quality of life compared to patients undergoing long-term dialysis treatment 5,6.
Renal transplantation is also the most cost-effective long-term treatment for ESRD,
saving a minimum estimated $100,000 CAD per patient (depending on donation type)
over the entire course of treatment compared to dialysis 7-9. Thus, considering the longterm survival, quality-of-life and economic benefits compared to dialysis, renal
transplantation is the preferred modality of treatment for ESRD.

1.2 Challenges in Renal Transplantation
Currently, the primary challenge limiting the implementation of renal transplantation for
ESRD patients is the lack of available donor organs. Corresponding to increased
prevalence of chronic diseases such as diabetes and hypertension, the need for renal
transplantation has been compounded over the past 10 years. During this period, renal
transplant waiting lists have grown by 30% in Canada and 92% in the United States 3,10.
In contrast, rates of kidney donation and transplantation have remained stagnant in North
America, creating an increasing discrepancy between the number of patients receiving
dialysis and those with a functioning transplant 3,10. This discrepancy manifests as longer
wait times and increased mortality for ESRD patients on transplant waiting lists 3,10.
Kidney Donor Pools
The current kidney donor pool consists of both living and deceased donors. Living
donation represents the optimal clinical situation, as the donor kidney is able to be
procured and transplanted in quick succession, allowing for very limited periods of
damaging ischemia. However, candidates for living donation are more difficult to find
and deceased donors represent about two-thirds of all kidney donations in the United
States and one-half of all kidney donations in Canada 3,10. As the need for donor kidneys
outstrips the supply, clinicians have sought to further expand the donor kidney pool
through increased use of “marginal” donor kidneys previously thought to be unsuitable
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for transplantation. While factors such as potential for transfer of infectious agents and/or
malignancy immediately rule out a potential donor, other detrimental characteristics, such
as cause of donor death (circulatory vs. cerebral), poor functional renal profile (high
serum creatinine), increased donor age and presence of co-morbidities, may represent
acceptable risks for renal transplantation compared to continuing dialysis 11,12. There are
currently two major categories of “marginal” donors: expanded criteria donors (ECD)
and donation after circulatory death (DCD). Both ECD and DCD represent deceased
donors, however ECD donors can be either age >60 or age 50-59 with up to two comorbidities such as hypertension, death from a cardiovascular event or serum creatinine
>130 µmol/L, while DCD donors have died from circulatory cessation prior to organ
procurement, which exposes donor organs to variable periods of injury caused by warm
ischemia 13. In comparison, a standard criteria deceased donor (SCD) is generally age
<50 with no prior history of hypertension or diabetes and an unrelated cause of death,
such as a motor vehicle collision, ensuring adequate blood circulation prior to organ
procurement 13. Of all deceased donors in the United States, ECD donors constitute
around 17%, while DCD donors have increased from under 5% to over 15% in the past
10 years, representing the fasting growing kidney donor population of any group 10. As
such, these “marginal” donors currently represent over one-third of all deceased donor
and their use is predicted to increase as more ESRD patients are placed on waiting lists.
Regrettably, due to their respective risk factors, use of ECD and DCD donor kidneys is
associated with increased rates of delayed graft function (DGF), defined as patient
requiring dialysis within 7 days following transplant, and decreased overall survival, with
5-year graft survival rates of 64% for ECD and 54% for DCD kidneys compared to 77%
for SCD kidneys in the United States 10. However, despite inferior clinical outcomes
compared to SCD kidneys, transplantation of “marginal” donor kidneys has still proven
to provide a cost and survival benefit compared to dialysis 14 and augmenting the
effectiveness of these transplants represents a crucial opportunity to improve clinical
treatment of ESRD.
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1.3 Ischemia-Reperfusion Injury in Renal Transplantation
Pathophysiology of Renal Ischemia-Reperfusion Injury
Another major obstacle to the success of clinical renal transplantation is that donor
kidneys are exposed to varying periods of a specific type of injury inherent to
transplantation, ischemia-reperfusion injury (IRI). Renal IRI is a distinct
pathophysiological process and occurs during the peri-transplant period, when renal
blood flow is removed upon procurement (ischemia) and subsequently restored upon
transplantation (reperfusion). Organ procurement from deceased donors must be
performed in a limited time frame and can occur in a geographically disparate region
compared to the recipient. Due to these logistical hindrances, deceased donor kidneys are
frequently transported over great distances and are thus exposed to longer periods of
ischemia compared to living donors. During this ischemic period, lack of nutrients and
oxygen (O2) from blood result in depletion of ATP levels causing depolymerisation of the
actin cytoskeleton as well as dysfunction and ultimate loss of ATP-dependent membranebound ion transporters 15,16. Dysfunction of these cellular components causes loss of tight
junctions and cellular polarity in renal tubular epithelial cells, responsible for
reabsorption of nutrients and secretion of waste substances into urine, and microvascular
endothelial cells leading to dysregulation of renal blood flow, tubular back-leak and
impairment of kidney filtration capacity 17-19. Mitochondrial dysfunction is another
hallmark of renal ischemia, resulting from electron transport chain (ETC) inhibition,
causing loss of membrane potential as well as cytosolic calcium (Ca2+) influx and leading
to mitochondrial swelling 20,21. Upon reperfusion, mitochondrial ETC function remains
impaired at complex I and is unable to handle the excessive O2 influx causing a burst of
reactive oxygen species (ROS) production 22,23. Activation of the oxidizing enzyme
xanthine oxidase is also implicated as a source of ROS production during reperfusion 24.
ROS-mediated mitochondrial membrane damage and Ca2+-induced mitochondrial
swelling then lead to formation of the mitochondrial permeability transition pore (MPTP)
complex, cytochrome c release and caspase-mediated cellular apoptosis 25,26. Induction of
inflammation is also an important mediator of renal injury during IRI. Renal tubular
epithelial cells (TEC) release various pro-inflammatory cytokines during IRI as a result
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of ROS-mediated NF-κB signaling and vascular endothelial cells upregulate surface
expression of important adhesion factors intercellular adhesion molecule 1 (ICAM-1) and
E-selectin 27-30. Pro-inflammatory cytokines produced from injured TEC further stimulate
release of Fas ligand (FasL) which binds to Fas receptor (FasR) on the surface of
neighbouring TEC and activates Fas-mediated cellular apoptotic signaling pathways in an
autocrine fashion 31. Restoration of blood flow also brings innate immune cells,
specifically pro-inflammatory polymorphonuclear (PMN) cells, which home to inflamed
renal tissue and release proteolytic enzymes as well as additional ROS, further damaging
renal tissue and mediating apoptosis and necrosis 32,33. These complex pathophysiological
processes comprising renal IRI, involving numerous phases and mechanisms of tissue
injury, are graphically depicted in Figure 1.1.
Prevention of Ischemia-Reperfusion Injury during Renal Transplantation
Due to inferior initial health compared to SCD kidneys, ECD and DCD kidneys are
associated with worse clinical outcomes partly because they are more susceptible to
damage associated with IRI during transplantation. Also, considering that over 40% of
ECD kidneys are currently discarded upon receipt by transplant surgeons due to
accumulation of injury and insufficient function, minimizing IRI is especially important
to maximize the utility of these “marginal” donor kidneys 10. Current strategies of
mitigating IRI during the peri-transplant period involve the use of cold (0ºC to 4ºC) organ
storage in conjunction with organ preservation solution. Storage of organs at cold
temperatures limits the impact of ischemia during transplantation by slowing cellular
metabolism, thereby reducing ATP consumption and build-up of acidic metabolic waste
products, and decreasing the rate at which enzymes degrade key cellular components 34.
However, hypothermic storage is also associated with tissue swelling due to suppression
of Na+ pumps and disruption of cellular osmotic balance 34. Therefore, current practice is
to employ organ preservation solution during hypothermic storage, which are generally
pH-buffered, osmotically balanced solutions that contain impermeant substances which
maintain cellular osmolality and prevent swelling. While there are multiple preservation
solutions available for clinical use, University of Wisconsin (UW) solution is the most
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Figure 1.1 Pathophysiology of renal ischemia-reperfusion injury during
transplantation.
Renal ischemia-reperfusion injury (IRI) is initiated when blood supply is removed from
the donor kidneys upon procurement (ischemia), depriving renal cells of oxygen (O2) and
ATP. This metabolic deficit results in mitochondrial injury/dysfunction, release of proinflammatory cytokines from renal epithelium and consequent endothelial expression of
adhesion factors. When blood supply is reinstated to the donor kidney (reperfusion),
bursts of ROS are produced from malfunctioning mitochondria and innate immune cells
are adhere to inflamed renal endothelium and extravasate to the interstitial space, where
they release damaging ROS and proteases. Renal injury resulting from these injurious
phenomena cause tissue necrosis and trigger cellular apoptotic pathways, which result in
renal cell death and renal graft dysfunction in the acute post-transplant period.
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common and continues to perform as well or better than more recently developed
preservation solutions 35. UW solution was developed at the University of Wisconsin by
Drs. Belzer and Southard during the 1980’s and was first shown to effectively preserve
canine kidney and liver grafts during hypothermic organ storage and extend viable
periods of cold storage compared to contemporary preservation solutions 36,37. Since that
time, UW solution has been used to improve preservation of all abdominal organs during
human clinical transplantation 38. UW solution is a phosphate-buffered solution that
contains impermeant molecules, raffinose and lactobionate, and the colloid, hydroxyethyl
starch, which preserve tissue osmotic balance and prevent organ edema by virtue of being
unable to pass through the semi-permeable glomerular basement membrane, thus
maintaining glomerular osmotic pressure at physiological levels 34. Also included in UW
solution is adenosine, a substrate thought to kick-start oxidative phosphorylation upon
reperfusion, anti-oxidant molecules glutathione and allopurinol, as well as the antiinflammatory, dexamethasone, and the antibiotic, penicillin 34. These additional
substances added to UW solution help to blunt the initial oxidative stress and
inflammation that follows reperfusion of grafts.
While the advent of UW solution greatly improved efficacy of cold organ storage, few
significant advances have been made to cold organ preservation since that time. One
major progression in renal graft preservation has been the use of pulsatile perfusion (PP)
pumps during cold storage. Pulsatile perfusion mechanically pumps preservation solution
through donor organs using a bimodal perfusion pressure pattern (mimicking normal
systole and diastole) in an effort to deliver nutrients to organs and remove metabolic
waste products during cold preservation 39. Opinions have remained somewhat mixed on
the benefit of cold PP, with some studies showing that use of PP during donor kidney
preservation can mitigate the risk of subsequent renal graft DGF and others reporting no
benefit on DGF rates with PP compared to static cold storage 40-43. While these
differences may depend on variations in donor types and transplant centre guidelines, the
increased difficulty of use and complexity of preservation solutions, which must include
oxygen carriers, combined with a potentially modest clinical benefit has prevented PP
from becoming the standard of care for renal transplantation. In addition, use of PP has
not eliminated clinical complications of cold IRI as prolonged cold ischemia time (CIT)
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continues to be associated with increased rates of DGF and decreased graft function and
survival regardless of storage method 43. Cold ischemia time can vary widely depending
on specific transplant centre guidelines, with reports of average donor kidney CIT
between 14-24 hours and prolonged (>24 hours) CIT rates ranging from ~10% to >30%
of all transplants 43-47. These previous studies also show that prolonged CIT rates are
significantly associated with deceased organ donation and greater distance traveled by
donor kidneys. Unsurprisingly, donor kidneys exposed to >24 hour periods of CIT are
associated with elevated acute tubular necrosis (ATN) levels, increased rates of graft
rejection and decreased long-term graft function and survival 44,48. Additionally, a
previous paired analysis of ECD donor kidneys revealed that increasing CIT by 4 or more
additional hours predicted heightened rates of DGF compared to counterpart donor
kidneys 46. Thus, donor kidney CIT is positively correlated with incidence of negative
clinical transplant outcomes and risk of detrimental sequelae increases continuously as
renal graft CIT is extended. With cold storage times predicted to increase as transplant
centres expand organ sharing networks, prolonged CIT continues to represent a major
obstacle to improving the clinical outcomes of renal transplantation.

1.4 Gasotransmitters
Classification of Gasotransmitters
One recently promising therapeutic strategy to mitigate the detrimental effects of
prolonged cold IRI in renal transplantation has been the application of gasotransmitters
during the peri-transplant period. Gasotransmitters are small gaseous molecules that,
while previously known only as environmental pollutants, have recently been found to be
endogenously produced in mammals via the actions of various enzymes using cellular
substrates 49. By definition, gasotransmitters are not only gaseous, but are also present in
tissue at very low levels, permeable to cell membranes, requiring no membrane-bound
receptors for cellular entry, and exhibit well-defined cellular functions at physiological
levels, including cellular signaling and vasodilation 49. The first molecule to be classified
as a gasotransmitter was nitric oxide (NO). Due to its first discovery as an endotheliumderived relaxing factor over 30 years ago, NO has been the most well studied member of
the gasotransmitter family 50. Subsequently in 1991, endogenously produced carbon
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monoxide (CO) was discovered to exhibit similar cellular signaling and vasodilatory
actions as NO and was subsequently classified as the second member of gasotransmitter
family 51. These two gasotransmitters have been studied extensively in the context of
normal cellular physiology as well as in numerous and varying disease and injury models.
In addition to their important physiological roles, NO and CO have been shown to exhibit
cytoprotective effects during ischemic injury through modulation of inflammation,
oxidative stress and apoptotic signaling pathways 52. These protective effects against the
pathophysiological mechanisms of IRI have led to the recognition of NO and CO as
promising potential therapeutic molecules for the protection of grafts against IRI during
renal transplantation 53.
Hydrogen Sulfide as a Gasotransmitter
The successful and ground-breaking research investigating the physiologic and
therapeutic properties of NO and CO consequently set in motion the search for other
novel physiological gases with similar properties. This pursuit yielded the discovery that
the gaseous molecule hydrogen sulfide (H2S) is endogenously produced in mammalian
tissue and exhibits similar cellular signaling and vasodilatory properties as NO and CO,
ultimately leading to its classification as the third gasotransmitter 49. Prior to this
discovery, H2S had long been known as an industry-derived environmental hazard, which
exerts toxic effects at high levels via inhibition of cytochrome C oxidase in the ETC,
leading to arrest of cellular respiration 54. The physiological relevance of H2S only
became apparent in 1996, when it was observed to modulate N-methyl-D-aspartate
(NMDA) receptor-mediated functions in the hippocampus 55. By this time it had already
been determined that cellular H2S is produced mainly through metabolism of the sulfurcontaining amino acid, cysteine, via the actions of three major enzymes: cystathioninebeta-synthase (CBS), cystathionine-gamma-lyase (CSE) and 3-mercaptopyruvate
sulfurtransferase (3-MST) 56. While CBS and CSE are present in cytosol and 3-MST
localizes to mitochondria, all three H2S-producing enzymes have been reported to be
ubiquitously expressed in the majority of human cell types to varying degrees 56.
Correspondingly, H2S is thought to be in the nanomolar to micromolar range within the
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blood, further solidifying the claim of H2S as a physiologically relevant gaseous molecule
57

.

Interactions between Gasotransmitters
Considering the similarities in chemical properties within the gasotransmitter family, it is
not surprising that much recent research has focused on the potential biological
importance of interactions between NO, CO and H2S. Depending on cellular conditions,
gasotransmitters have the ability to either enhance or impede the cellular effects of its
other family members via inhibition of enzymatic gaseous production, modulation of
downstream signaling pathways and/or direct gas-to-gas interaction 58. It is well known
that gasotransmitters have a high binding affinity for heme due to interactions with Fe2+
ions, and can thus modulate the activity of heme-containing enzymes such as NOproducing nitric oxide synthases (NOS), CO-producing heme oxygenases (HO) and the
H2S-producing enzyme, CBS 59. While H2S treatment increases HO expression/CO
production and binding of NO and CO to CBS has been shown to enhance H2S
production, binding of CO and H2S to various NOS isoforms have conversely been
shown to inhibit NO production 60-64. Complicating matters further, addition of
exogenous H2S can indirectly stimulate NO production through promotion of endothelial
NOS (eNOS) phosphorylation via PIK3-Akt signaling, stimulation of eNOS activity via
release of endoplasmic reticulum Ca2+ stores and upregulation of IL-1β-mediated
inducible NOS (iNOS) expression 65-67. The circumstantial details that dictate modulation
of counterpart gas production are complex and remain incompletely understood, however
it is clear that this co-regulatory effect could be an important mechanism through which
gasotransmitter interaction can impact many cellular pathways. Another important
interaction between gasotransmitters is through modulation of activity of downstream
signaling molecules, such as cyclic guanosine monophosphate (cGMP). It has long been
known that the potent vasodilatory effect of NO is mediated by activation of the enzyme
guanylate cyclase (GC) and its subsequent synthesis of the secondary messenger cGMP
from guanosine triphosphate (GTP) 68. It has been more recently shown that CO can also
potentiate vasodilation through activation of GC to produce more cGMP, though this
effect is much less potent compared to that of NO 69. It has also been recently put forth
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that H2S can alternatively maintain cellular cGMP levels through inhibition of the cGMPdegrading enzyme phosphodiesterase-5 (PDE5), further enhancing cGMP-mediated
vasodilation stimulated by NO and CO 70-72. Thus, the potential interactions between NO,
CO and H2S could have widespread cellular consequences as a result of functional
modulation of an array of interrelated secondary signaling molecules.
The potential cellular interactions between NO and H2S have received the most scrutiny
in recent studies and could represent an important process in the induction of
physiological pathways attributed to both of these gases 73. Rather than simply aiding or
impeding the other’s cellular effects, it has been recently demonstrated that some
biological effects of NO and H2S are mutually dependent and cannot occur without both
gases present. Recent reports have shown that separate inhibition/knockout of enzymes
producing the counterpart gasostransmitter strikingly abolishes physiological effects
normally observed by exogenous administration of NO or H2S, including pro-angiogenic
and vasodilatory actions as well as cardioprotective effects in models of heart failure and
myocardial IRI 72,74-76. While this phenomenon could potentially be due to co-dependent
modulation of important gasotransmitter signaling molecules as previously described, it
is also possible that the direct interaction of NO and H2S is required to mediate their
downstream physiological effects. The first report of a chemical reaction between NO
and H2S was put forth by Whiteman, et al. who demonstrated that interactions between
both exogenous and endogenous NO and H2S can result in the formation of a novel
nitrosothiol (RSNO) molecule 77. Nitrosothiols are reactive groups whose chemical
addition onto protein sidechains have previously been implicated in induction of NOmediated signaling pathways such as vasodilation 78. However it has also been shown that
H2S and NO can react to form the smallest possible nitrosothiol molecule, thionitrous
acid (HSNO), which could potentially influence H2S and NO signaling independent of
other signaling molecules 79. Thus, while the interplay between gasotransmitters has only
begun to be characterized, these interactions appear to serve crucial roles in mediating the
respective physiological and therapeutic effects of each family member. It will be
important for future studies investigating the physiology of only one gasotransmitter to
acknowledge that other gasotransmitters could be playing equally important roles in any
given biological system.
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1.5 Actions of Hydrogen Sulfide in the Kidney
Global Physiological Effects of Hydrogen Sulfide
In addition to serving its role as a neuromodulator of long term potentiation, H2S is
produced systemically and serves pleiotropic functions within the cardiovascular system,
kidneys, liver, pancreas, gastrointestinal system, urinary system and reproductive system
80-86

. The physiological effects of H2S in the context of these organ systems are

summarized in Table 1.1. H2S acts on these biological systems via two primary means:
potentiation of vasodilation and modulation of cellular signaling pathways. Vasodilatory
effects of H2S have been shown to result from inhibition of PDE5 to increase cellular
cGMP levels, as previously described, as well as activation of KATP ion channels on the
surface of vascular endothelium and smooth muscle cells, a mechanism not shared by
either CO or NO 71,87. Alternatively, modulation of cellular signaling by H2S occurs via
alterations in the activity and expression of proteins from multiple signaling pathways
involved in apoptosis, inflammation, angiogenesis, proliferation, metabolism, oxygen
sensing and oxidative stress 88. The biochemical mechanisms by which H2S is able to
alter cellular physiology are as diverse as the downstream effects induced. Such
mechanisms include; i) regulation of kinase, transcription factor and ion channel activity
via post-translational S-sulfhydration of cysteine residues and through the production of
polysulfides ii) binding of heme in heme-containing proteins, iii) scavenging of reactive
oxygen species (ROS) and iv) donation of electrons to the mitochondrial electron
transport chain (ETC) to fine tune bioenergetics 81,89-91. Whether the production of H2S is
finely regulated in order to exert specific cellular responses is still up for debate, however
it is clear that this gaseous molecule is at least serving as a homeostatic sensor capable of
regulating several aspects of cellular physiology 88. With such a wide array of functions,
it is not surprising that disruption of endogenous H2S synthesis has been implicated in
pathologies such as Alzheimer’s disease, Down syndrome, hypertension, cancer, chronic
kidney disease (CKD), diabetes and aging 57. Despite the fact that research on this
molecule is still in its infancy, a strong base of evidence supporting the therapeutic value
of exogenous sources of H2S has already been established 92.
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Table 1.1 Physiological effects of hydrogen sulfide by organ system.
Organ System
Physiological Effect(s)
Central Nervous  Facilitates NMDA receptor-mediated signaling
and hippocampal long-term potentiation
potentially via sulfhydration of NMDA receptors
 Induces astrocyte Ca2+ influx, stimulating release
of D-serine and subsequent enhancement of
NMDA receptor activity
Peripheral
 Dose-dependently modulates nociception through
Nervous
interactions with T-type Ca2+ channels and
TRPA1 ion channel signaling
Cardiovascular
 Promotes vasodilation through relaxation of
vascular smooth muscle via activation of K+ATP
ion channels
 May cause vasoconstriction at lower levels (10100 µM) and vasoactive effects depend on ppO2
 Induces angiogenesis via stimulation of VEGF
and Akt signaling pathways
Renal
 Increases renal blood flow and stimulates diuresis
and electrolyte excretion
 May function as an O2 sensor in renal medulla
through HIF signaling
 Possibly a physiological modulator of reninangiotensin pathway via alterations in cAMP
and/or ROS signaling
Hepatobiliary
 Potential positive regulation of lipid metabolism
and negative regulation of glucose metabolism
 Maintains hepatic perfusion through
microcirculatory vasodilation
 Participates in regulation of bile formation via
modulation of biliary bicarbonate excretion
Pancreatic
 Negatively regulates glucose-dependent insulin
release from β-islet cells possibly via modulation
of K+ATP and Ca2+ channel activity
Gastrointestinal  Potential regulatory roles in intestinal contractility
and gastric secretion
 Promotes healing of gastric ulcers
Urinary
 Mediates bladder relaxation at low (25 µM-75
µM) levels and bladder contraction at higher (300
µM-3 mM) levels
 Effects could be mediated by TRPA1 ion channel
activation or hypoxia signaling pathways
Reproductive
 Facilitates sexual function via cavernosal
relaxation in penile, vaginal and clitoral tissue
 Stimulates relaxation of vas deferens via
activation of BKCa ion channels
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Physiological Roles of Hydrogen Sulfide in the Kidney
While a physiological role for H2S was not documented until 1996, the production of H2S
in mammalian tissue was originally documented by Stipanuk and Beck in 1982 129. In
addition to the liver, brain, heart and skeletal muscle, they identified the kidneys as a
major producer of H2S, concluding that under physiological conditions all three enzymes
are involved in H2S production, with CSE being the major contributor 129. While the
authors did not characterize the localization of these enzymes within the kidney, further
work eventually established that CBS, CSE and 3-MST are primarily present in proximal
tubules within the renal cortex 130-132. More recently, it has been noted that CBS primarily
localizes to the proximal convoluted tubule in the outer cortex whereas CSE localizes
most prominently to the proximal straight tubule in the inner cortex as well as to the outer
medulla 133,134. One possible explanation for the difference in localization of CSE and
CBS is that CSE is required for the catabolism of cysteine that arises from glutathione
synthesis in the proximal straight tubule of the nephron 130. An additional observation by
Ishii et al. illustrates that CSE expression is strongly induced in the proximal straight
tubule during murine development and then regresses to 50% of its peak expression,
suggesting a possible role for CSE in facilitating development of the nephron 133.
While it has long been known that the H2S-producing enzymes are essential in the kidney
due to the role they play in metabolizing homocysteine (Hcy), a functional role for H2S
itself in normal kidney physiology was only recently investigated 82. Using an intra-renal
arterial infusion model in rats, Xia et al. demonstrated that both CSE and CBS are
involved in regulating baseline hemodynamics and tubular properties, with renal H2S
concentrations correlating with increased renal blood flow (RBF), glomerular filtration
rate (GFR), urinary excretion, natriuresis and kaliuresis 82. Possible mechanisms of the
renal actions of H2S could include induction of vasodilation in the case of increased RBF
and GFR, and inhibition of the tubular Na+/K+ ATPase (NKA) and the Na+/K+/2Cl- Cotransporter (NKCC) in the case of natriuresis and kaliuresis 82. Baseline renal H2S
production may also control the renin-angiotensin system (RAS), either directly by
altering cAMP production, or indirectly via regulation of ROS, possibly affecting global
hemodynamic parameters 108,109. Thus, it is possible that renal H2S production may be a
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homeostatic cellular response to changes in physiological parameters, though further
investigation is required to identify which alterations to the physiological balance elicit
renal H2S production.
Although various studies have shown that glomerular injury can be attenuated through
H2S therapy 135,136, H2S-producing enzymes are noticeably lacking in glomerular
epithelial cells 132-134. It has recently been observed that baseline expression of H2S in
glomerular epithelial cells (GECs) may be important in regulating global protein
synthesis through AMP-activated protein kinase (AMPK) and mammalian target of
rapamycin complex 1 (mTORC1). Given the membrane permeability and paracrine
nature of H2S, it is possible that production of H2S in nearby proximal tubular epithelial
cells or vascular endothelium could be sufficient for the needs of GECs, thus making it
unnecessary for H2S to be produced in the glomerulus itself 136. Similarly, proximal
tubule capillaries (PTCs) have been observed to vasodilate in response to exogenous H2S
while they themselves do not express CBS nor CSE. Given the lack of smooth muscle
cells in these capillaries, it was speculated that proximal tubule-derived H2S also
regulates the diameter of these structures 132.
It has recently been proposed that H2S may act as an oxygen sensor in the renal medulla
105

. This hypothesis is based on the fact that H2S is readily oxidized under normoxic

conditions, being the only known inorganic contributor of electrons to the ETC, but is
permitted to accumulate in the reducing environment of mitochondria that is present
under periods of hypoxia 137. Once H2S accumulates in the medulla as a result of
decreased oxygen tension, Beltowski proposed that it then functions to restore the oxygen
balance by inhibiting Na+ transport – which is responsible for 60% of renal oxygen
consumption) – and inducing vasodilation of the descending vasa recta 105. We and others
have shown that the oxygen sensing capacity of H2S may also be mediated by specific
modulation of hypoxia inducible factor (HIF) signaling pathways 106,107. The possible
oxygen sensing capacity of H2S could be very important for renal function given that the
medullary thick ascending limb harbours the majority of NKCC channels, expresses
moderate amounts of CBS and requires finely tuned regulation of blood flow to maintain
the balance of hyperosmolality and oxygen supply for urine concentration 134.

18

Thus, it has clearly been identified that H2S is produced at high levels in the kidneys
under normal physiological circumstances and is an important player a number of aspects
of renal physiology, though specific mechanisms and additional roles of the renal effects
of H2S must be further elucidated.
Protective Effects of Hydrogen Sulfide against Warm Renal IRI
In addition to its numerous physiological actions, H2S has been shown to play a major
cytoprotective role during various forms of tissue injury. Hydrogen sulfide exhibits antiapoptotic effects through down-regulation or deactivation of pro-apoptotic signaling
molecules bcl-2 like protein 4 (BAX), mitogen-activated protein (MAP) kinase (p38), cJun N-terminal protein kinase (JNK) and caspases 3 and 9, while upregulating the
expression of the anti-apoptotic signaling molecule B-cell lymphoma 2 (Bcl-2) 138,139. As
well, H2S can dampen inflammation by inducing neutrophil cell death and inhibiting
leukocyte adherence to inflamed endothelium 140,141 and mitigates oxidative stress by
directly inhibiting reactive species and increasing cellular levels of the anti-oxidant
protein glutathione 142,143. While these protective effects were shown in a variety of
tissue types, it is also known that H2S acts as a specific modulator of the renal oxidative
stress response. This occurs through both upregulation/potentiation of antioxidants like
Nrf-2, superoxide dismutase (SOD), catalase, glutathione, apocynin and N-acetyl-Lcysteine, and through down-regulation of ROS-generating enzymes such as NADPHoxidase 144. In addition, D’Araio et al. showed that expression of the antioxidant heme
oxygenase-1 (HO-1) is upregulated in human mesangial cells and podocytes treated with
various H2S donor molecules 145. Considering its important role in normal renal
physiology, as well as its potent cytoprotective actions during tissue injury, H2S has been
identified as a potential therapeutic strategy to mitigate renal damage associated with IRI.
As well, considering its stimulatory role in cellular bioenergetics at physiological levels,
it is thought that H2S could provide more potent protection against IRI compared to NO
or CO, which lack this ability.
Previous studies investigating the protective effects of H2S against renal IRI have been
performed in the context of warm IRI induced by clamping of the renal pedicle for
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varying periods of time and allowing kidneys to reperfuse. The first study to show that
H2S could play a protective role in warm renal IRI was conducted by Tripatara et al. in
2008 and utilized a murine model of warm renal IRI in which both kidneys were clamped
for a period of 45 minutes and subsequently allowed to reperfuse for 6 hours. In this
study, pharmacological inhibition of the endogenous H2S producing enzyme, CSE,
significantly worsened renal dysfunction associated with bilateral warm renal IRI and
that renal function could be somewhat recovered by treatment with exogenous H2S
during IRI via the sulfide salt NaHS. H2S treatment also resulted in decreased levels of
ATN and decreased activation of pro-apoptotic markers caspase-3, BH3 interacting
domain death agonist (BID), JNK1/2 and pro-inflammatory markers NF-κB, ICAM-1,
inducible nitric oxide synthase (iNOS) and cyclooxygenase 2 (COX-2). Interestingly,
H2S also decreased the expression of anti-apoptotic markers Bcl-2 and extracellular
signaling kinase 1/2 (ERK-1/2), though this could be potentially be reflective of an
overall decreased state of cellular apoptosis 146.
Subsequently Bos et al. conducted a study investigating H2S and warm renal IRI which
utilized a novel method of induction of a hypometabolic, hibernation-like state in mice
via inhalation of 500 ppm H2S gas, which represents a non-lethal, but potentially
injurious dose 54. This study demonstrated that induction of hypometabolism via H2S
inhalation prior to 30 minutes of bilateral warm renal clamping significantly improves
resultant survival and renal function and decreases renal necrosis and inflammation.
Importantly, the authors demonstrated that only treatment of mice with H2S before and
during renal IRI exhibited a significant protective effect, whereas very limited to no
protective benefit was seen in mice only treated after warm IRI 147. Bos et al. have also
recently shown that transgenic mice lacking expression of CSE (CSE-/-), which exhibit a
50% reduction in serum H2S, are more susceptible to bilateral warm renal IRI and exhibit
significantly decreased renal function and survival and increased renal injury and
inflammation after 24 hours compared to wildtype. These detrimental effects seen in
CSE-/- mice were significantly reversed upon intraperitoneal treatment of mice with
NaHS. The authors also found that both over-expression of CSE in human embryonic
kidney 293 (HEK293) cells and supplementation with NaHS reduced ROS-production in
response to antimycin treatment in vitro 148.
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Our laboratory has previously demonstrated that direct treatment with NaHS protects rat
kidneys during 60 minutes of unilateral warm renal IRI following contralateral
nephrectomy. In our study H2S treated animals exhibited significantly decreased (p<0.05)
serum creatinine levels and increased renal perfusion as well as decreased renal necrosis
and apoptosis compared to control following 2 hours of reperfusion. As well, H2S
treatment appeared to mitigate systemic inflammation associated with renal IRI as H2S
treated animals showed significantly decreased (p<0.05) serum levels of liver injury
markers aspartate aminotransferase (AST) and alanine aminotransferase (ALT) as well as
decreased numbers of rolling and adhering leukocytes in the liver compared to control
upon intravital microscopic analysis. These apparent anti-inflammatory effects of H2S
also correlated with significantly decreased (p<0.05) renal expression of proinflammatory markers toll-like receptor 4 (TLR-4), TNF-α, C-C chemokine receptor type
5 (CCR5), interferon γ (IFN- γ), interleukin 2 (IL-2) and interleukin 8 (IL-8). In addition,
treatment of human PMN with H2S in vitro significantly inhibited (p<0.05) their ability
to migrate across an endothelial monolayer in response to inflammatory stimulus 149. A
subsequent study showed that the acute protective benefits of H2S treatment during warm
renal IRI translate to longer term improvements that are sustained for at least 7 days, with
H2S treated animals exhibiting significantly (p<0.05) improved renal function and
decreased inflammatory infiltrate compared to control 150. Upregulation of endogenous
H2S production also appears to protect against warm renal IRI. Animals treated orally
with both L-cysteine and D-cysteine, precursors of endogenous H2S production, have
been shown to exhibit decreased renal injury following 30 min of unilateral renal
ischemia, with D-cysteine exhibiting more potent protective effects 151. Since D-cysteine
promotes H2S production through the mitochondrial DAO/3-MST pathway, it is possible
that mitochondrial preservation is an important protective mechanism of H2S during
warm renal IRI.
The protective effects of H2S against warm renal IRI have also been confirmed in porcine
models. Simon et al. first showed that intravenous H2S treatment prior to bilateral warm
renal IRI via intra-aortic balloon occlusion significantly improved renal hemodynamic
parameters and function, with H2S treated animals exhibiting significantly lower serum
creatinine after both 2 and 8 hours reperfusion. As well, H2S treated animals exhibited
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significantly decreased levels of pro-inflammatory markers TNF-α, interleukin 6 (IL-6)
and iNOS 152. Similar, but more sustainable effects were seen in a following study by
Hunter et al. in which pigs were exposed to 60 minutes of unilateral renal ischemia with a
contralateral nephrectomy performed at time of reperfusion. The authors show that H2S
treatment results in decreased serum creatinine levels between post-operative days 2-6 as
well as decreased tissue inflammation and lower levels of protein and neutrophil
gelatinase association lipocalin (NGAL) in the urine (important biomarkers of kidney
injury) 153.
Potential of Hydrogen Sulfide to Mitigate Cold IRI during Renal Transplantation
While the protective effects of H2S have been well established in the context of warm
renal IRI, a major gap in the current knowledge of H2S biology has been whether H2S can
exhibit similar protective effects during cold renal IRI indicative of clinical renal
transplantation. While numerous studies have demonstrated that NO and CO reduce graft
injury, inflammation, oxidative stress and apoptosis associated with both warm and cold
IRI and improved subsequent graft function and survival in models of murine and porcine
renal transplantation 154-160, only one previous study has attempted to investigate the
protective effects of H2S against cold renal IRI in the context of renal transplantation. In
this study, Hosgood and Nicholson developed an ex vivo model of DCD renal
transplantation in which pigs were sacrificed and kidneys were exposed to 25 minutes of
warm IRI in situ before being placed on a cold pulsatile perfusion pump for 18 hours and
subsequently transferred to an isolated organ preservation system (IOPS) at
normothermic temperatures for 3 hours to mimic organ reperfusion. Grafts were only
treated with NaHS for 10 minutes before and after reperfusion and parameters of graft
function were measured. H2S treatment significantly improved renal hemodynamic
parameters and GFR throughout the period of reperfusion compared to control. As well,
H2S treated grafts exhibited significantly decreased expression of 8-isoprostane, a marker
of oxidative stress, after 1 hour of reperfusion compared to control 161. This study was the
first to establish that H2S treatment during cold renal IRI can improve some parameters of
graft function following warm reperfusion. However, similar to previous studies
involving only warm IRI, this experimental model involved no actual transplantation of
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donor kidneys, which removes the inflammatory component of IRI pathophysiology and
does not fully represent the injury that accumulates in grafts during clinical renal
transplantation. Thus, while it is evident from previous studies that H2S could represent a
promising therapeutic strategy for ameliorating graft injury associated with prolonged
cold IRI during renal transplantation, this concept remains to be explored in a clinically
relevant model of renal transplantation.

1.6 Aims and Objectives
Our research aims to investigate whether addition of H2S to standard organ preservation
solution will mitigate renal graft injury associated with prolonged cold ischemia and
subsequent reperfusion, resulting in improved graft function and survival following
transplantation.
Aim 1 – Investigate whether supplementation of organ preservation solution with H2S
can mitigate prolonged cold IRI in a clinically relevant murine model of syngeneic
renal transplantation.
Objective 1.1
Characterize the in vivo protective effects of H2S supplementation during prolonged cold
organ storage on graft survival and physiological parameters of graft function following
syngeneic (genetically identical) renal transplantation.
Objective 1.2
Examine whether H2S treatment can reduce early tissue markers of renal graft injury,
inflammation and apoptosis following prolonged cold storage.
Aim 2 – Determine whether exogenous H2S treatment during moderate cold organ
storage can mitigate graft injury associated with cold IRI in the context of allogeneic
renal transplantation.
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Objective 2.1
Characterize the in vivo protective effects of H2S supplementation during moderate cold
organ storage on graft survival, graft function and early biomarkers of renal graft injury
following allogeneic (genetically dissimilar) renal transplantation.
Objective 2.2
Investigate whether H2S supplementation during cold organ storage impacts the
progression of renal graft rejection.
Objective 2.3
Determine how H2S treatment modulates the renal graft transcriptome in the acute phase
following transplantation.
Aim 3 – Characterize the protective effects of H2S during prolonged cold organ storage
in the context of allogeneic renal transplantation and investigate potential underlying
cellular mechanisms of H2S-mediated cytoprotection.
Objective 3.1
Characterize the in vivo protective effects of H2S supplementation during prolonged cold
organ storage on graft survival, graft function and early biomarkers of renal graft necrosis
and inflammation following allogeneic renal transplantation.
Objective 3.2
Investigate whether targeting of H2S release to mitochondria improves potency of
protective effects of H2S during in vitro hypoxia/hypercapnia and re-oxygenation injury.
Objective 3.3
Determine whether mitochondrial-targeted H2S donors can improve protection of renal
grafts during prolonged cold organ storage and subsequent transplantation in vivo.
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Chapter 2

2 Supplemental hydrogen sulfide protects transplant kidney
function and prolongs recipient survival following
prolonged cold ischemia-reperfusion injury by mitigating
renal graft apoptosis and inflammation
Ian Lobb 1,5, Amy Mok 1,5, Zhu Lan 2,5, Weihua Liu 3, Bertha Garcia 3 and Alp Sener 1,2,4,5
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Overview: This chapter utilizes a murine model of syngeneic renal transplantation to
demonstrate that addition of hydrogen sulfide, in the form of NaHS, to standard
University of Wisconsin (UW) solution significantly improves resultant graft function
and survival and mitigates renal tissue injury and inflammation associated with prolonged
cold organ storage compared to UW solution alone.
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2.1 Abstract
Renal grafts are invariably affected by ischemia-reperfusion injury (IRI) during
transplantation, resulting from removal of blood supply during procurement (ischemia)
and subsequent reinstatement (reperfusion) during engraftment. Prolonged periods of IRI
are associated with increased rates of delayed graft function, acute rejection and reduced
long-term graft survival. Hydrogen sulfide (H2S) is an endogenously produced molecule
recently described to have protective effects against warm ischemic tissue injury. We
hypothesized that supplementation of standard preservation solution with H2S would
mitigate transplantation-associated prolonged cold ischemia-reperfusion injury (IRI) in a
clinically applicable, in vivo model of renal transplantation (RTx). Following bilateral
native nephrectomy, Lewis rats underwent RTx with kidneys that were flushed with
either cold (4°C) University of Wisconsin (UW; UW group) or cold UW + 150 µM
NaHS (H2S group) solution and stored for 24 hours at 4°C in the same solution. Recipient
animals were monitored for a 14 day time course using metabolic cages to assess various
parameters of renal graft function. Renal grafts were removed at time of death or sacrifice
for histological, immunohistochemical and qPCR analysis. H2S treated animals exhibited
immediate and significant (p < 0.05) decreases in serum creatinine levels, increased urine
output and increased survival compared to UW. H2S treated grafts showed significantly
reduced glomerular and tubular necrosis and apoptosis, diminished graft neutrophil and
macrophage infiltrates and a trend towards improved inflammatory and anti-apoptotic
cytokine profiles. Our results provide the first evidence that supplemental H2S can
mitigate renal graft IRI incurred during transplantation and prolonged cold storage,
improving early graft function and recipient survival in a clinically applicable model of
RTx.
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2.2 Introduction
Ischemia-reperfusion injury (IRI) has a significant impact on both early and long-term
graft function and survival, and is unavoidable in the peri-transplant period. Cold renal
graft ischemia has been linked to acute tubular necrosis (ATN) and significant glomerular
injury, whereas warm reperfusion is associated with induction of inflammatory mediators
and reactive oxygen species 1-4, which further accentuate tissue damage. With more
transplant centres accepting and utilizing grafts near the limits of cold ischemic times to
accommodate their expanding waiting lists, the ensuing delayed graft function and
decreased long-term graft survival is becoming more prevalent 5;6. Moreover, the growing
disparity between the number of patients on the renal transplant waiting list have led to
an increase in the use of organs procured from donors after cardiac death (DCD) as well
as from expanded criteria donors (ECD) 7. These “marginal” donor organs are more
susceptible to IRI compared to standard criteria organs 8;9. Recent data from ECD
kidneys shows 10-year graft and patient survival rates of 29% and 47%, compared to
46% and 64% for non-ECD kidneys, respectively 7. Considering that ECD, DCD and
ECD-DCD kidneys currently make up approximately 30% of all kidney transplants
performed in the USA 7, minimizing the degree of IRI-induced cellular damage during
cold storage is of critical importance in improving transplant outcomes.
Recently, treatment of ischemic tissues with gasotransmitters has become a promising
avenue in minimizing IRI. Gasotransmitters are a relatively newly classified family of
small gaseous molecules that, while initially thought to produce only toxic effects, have
been found to be endogenously produced and possess many important physiological
properties. Nitric oxide (NO) and carbon monoxide (CO) had been the two prominent
members of this family of molecules, until the recent induction of hydrogen sulfide
(H2S). While gasotransmitters have separate distinct physiological functions, all family
members generally exhibit cellular signalling, vasodilatory and anti-inflammatory
properties at low concentrations as well as the ability to decrease cellular respiration via
interactions with cytochrome c oxidase and other mitochondrial enzymes 10. These key
properties generated the notion that gasotransmitters may be effective in limiting cellular
and tissue damage by IRI. Nitric oxide is the best studied gasotransmitter and has been
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found to be cytoprotective in various models of tissue IRI, including myocardium 11,
intestine 12;13 and liver 14. As well, CO has been shown to be cytoprotective in models of
cold intestinal IRI and myocardial and renal transplantation 15-17.
H2S has long been known for its unsavoury smell and toxic effects at high concentrations.
However, it has been noted that H2S levels are elevated in hibernating animals and high
levels of exogenously administered H2S can induce a hibernation-like state of suspended
animation in non-hibernating animals 18, stimulating the idea that H2S has beneficial
endogenous roles as well. Indeed, H2S has recently been shown to be produced
endogenously at low concentrations in humans and other animals and has been implicated
in many important physiological functions such as cellular signalling 19;20. Similar to the
other gasotransmitters, exogenous H2S has been observed to be cytoprotective in models
of myocardial 21, cerebral 22, lung 23 and hepatic 24 IRI. While H2S has been shown to be
protective against warm renal IRI 25, the effects of H2S in mitigating prolonged cold renal
IRI have not yet been characterized in an in vivo model of renal transplantation.
The present study utilizes an in vivo model of renal transplantation to demonstrate that
supplementation of standard organ preservation solution with exogenous H2S is
protective against renal graft IRI, even at prolonged periods of cold storage, leading to
increased early graft function, improved renal tubular function and overall survival. This
protection appears to be mediated via anti-inflammatory and anti-apoptotic actions of
H2S. The results herein suggest that the administration of exogenous H2S during organ
storage may have significant clinical applicability and provide a protective benefit in
reducing IRI in transplanted kidneys to potentially improve both short and long-term
graft and patient survival.
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2.3 Materials and Methods
Experimental animals
Male Lewis rats were purchased from Charles River Canada and used at 225 – 250 grams
(n=16). Rats were maintained in the Animal Care and Veterinary Services facility at the
University of Western Ontario (London, ON) under standard conditions approved by the
Animal Use Subcommittee.
Surgical procedure and post-operative monitoring of rats
Syngeneic Lewis rats were transplanted to eliminate any confounding effects of
immunosuppression. Rats were anaesthetized with isofluorane and using aseptic
techniques, kidneys were exposed through a midline incision. Donor kidneys were
obtained as per the following: descending aorta was exposed and cannulated with a 28G
angiocath, inferior vena cava (IVC) and aorta were clamped above the renal hilum and
the descending IVC was cut at level of pelvic bifurcation. By convention, left kidneys
were always used for donation. The donor kidneys were then flushed through the cannula
with 25 mL of either cold (4 °C) standard University of Wisconsin (UW) preservation
solution (UW, n=4) or cold UW plus H2S donor molecule (150 µM NaHS (Sigma))
solution (H2S, n=8) until effluent from the cut portion of IVC was clear then
subsequently placed in 50 mL of the same perfusion solution and stored at 4 °C for 24
hours. The chosen dose of NaHS is within the therapeutic range demonstrated by
previous studies to be protective against warm and cold renal IRI 25;31. Sham operated rats
where only a midline incision was made were also followed to establish a baseline for the
measured variables (n=4). A 24h cold storage period was chosen as this represents an
extreme period of cold organ storage and has previously been shown to result in massive
ATN, apoptosis and inflammation that lead to graft loss and only 5% survival at 3 days in
rats treated with UW solution alone 17. Our aim was to assess the possibility that H2S
treatment could improve the function and survival of donor kidneys after extreme cold
storage and potentially extend the maximum allowable period of cold organ storage prior
to transplantation. Following bilateral nephrectomy, recipient rats underwent renal
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transplant (RTx) with donor kidneys removed from cold storage and transplanted
orthotopically into the left renal fossa using 10-0 prolene suture as previously described
26

. After RTx, rats were monitored in metabolic cages to assess urine output, water intake,

and urine and serum creatinine concentrations until time of sacrifice or until 14 days had
passed. The time course of 14 days was chosen as the majority of animals that survive
past 7-8 days post-transplant were observed to fully recover acute renal function and have
passed the acute time period in which we were most interested. At various time points
rats were removed from their metabolic cages and the previous 24 hours worth of water
intake as well as urine output was measured and collected for analysis of urine
physiology and GFR calculations. During this time 200 µL of blood was taken from the
tail vein of the rat, spun at 16,000 x g for 5 minutes to separate the serum and stored at 20 °C until analyzed for creatinine concentration. The length of surgery for the recipient
(including nephrectomy and kidney transplantation) was approximately 2-3 hours. There
was no difference in operative times between UW and H2S treatment groups. At the time
of death/sacrifice, all anastomoses were checked for any surgical complications that may
have resulted in variations in the results: none were found.
Creatinine and urine assays
Creatinine concentrations of serum obtained from RTx and Sham rats were determined
using the Creatinine-S system (Genzyme Diagnostics) in conjunction with a DU® 800
spectrophotometer (Beckman Coulter). Experimental creatinine concentrations were
determined using a standard curve method. Urine samples were analyzed at London
Health Sciences Center (London, ON). Urine protein and creatinine levels were
determined using the turbidimetric and enzymatic methods, respectively, performed on
the Roche Modular P instrument. GFR (mL/min) was calculated using the formula
(UxV/Px) and finally dividing by 1440 (number of minutes in 24 hours).
Histological staining
Renal grafts were removed from UW treated animals at time of death (post-operative day
3 to 5) and H2S treated animals either sacrificed between day 3 and 5 or at day 14. Half of
the sagitally bi-valved kidney was then placed in formalin for paraffin embedding and
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sectioning whereas the other half was flash frozen in liquid nitrogen and stored at -80 °C
for subsequent quantitative PCR (qPCR) analysis. Histological sections were stained with
hematoxylin and eosin (H&E) to assess degree of glomerular and renal tubular necrosis.
Terminal deoxynucleotidyl transferase dUTP nick end labelling (TUNEL) assay was used
to assess the degree of apoptosis present in renal allograft sections. Sections were scored
for necrosis and apoptosis out of 2, with 0 being normal, 0.5 minimum
necrosis/apoptosis, 1 mild necrosis/apoptosis, 1.5 moderate necrosis/apoptosis and 2
marked necrosis/apoptosis by a blinded transplant pathologist. Histological sections also
underwent immunohistochemical (IHC) staining. Sections were incubated with
antibodies against neutrophil-specific enzyme myeloperoxidase (MPO), macrophage
surface marker CD68 and T-cell surface marker CD3 (Abcam®) and visualized with
secondary antibodies and DAB substrate chromogen using the Dako Envision System
(Dako) as per manufacturer protocol. Positively stained cells in each FOV were counted
manually at 10X magnification. Five non-overlapping FOV were analyzed per section
and average numbers of positively stained cells per FOV were quantified.
qPCR analysis
Homogenized renal graft tissue was analyzed via qPCR. Samples from three animals per
treatment group were analysed in triplicate to determine the relative expression levels of
pro-inflammatory genes Interferon-Gamma (IFN-γ), Tumour Necrosis Factor-Alpha
(TNF-α) and Intracellular Adhesion Molecule-1 (ICAM-1), pro-apoptotic gene BH3
Interacting Domain (BID) and anti-apoptotic genes Extracellular Signal Kinase-1 and -2
(ERK-1 and ERK-2). The target gene signals were normalized against the
Glyceraldehyde -3-phosphate dehydrogenase (GAPDH) (Table 2.1). Renal graft tissue
stored at -80 °C was thawed immediately before use and homogenized with a mechanical
homogenizer. Total RNA was isolated from homogenized tissue using TriZOL®
(Invitrogen) and reverse transcribed into cDNA using Super Script II® Reverse
Transcriptase (Invitrogen) in conjunction with Oligo(dT)12-18 primers as per manufacturer
protocol. Isolated RNA and cDNA were analyzed via nanodrop before use, with A260/280
ratings consistently >1.95 and >1.8, respectively. The reaction mixture of each qPCR
sample had a volume of 20 µL and was composed as per SYBR® Green PCR Master Mix
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(Quanta Biosciences) protocol. All qPCR assays were performed and analyzed using
StepOnePlusTM Real-Time PCR thermal cycler and software package (Applied
Biosystems).
Statistical analysis
Survival data were analysed via Kaplan-Meier survival analysis and all other data were
analyzed via ANOVA, performed using the GraphPad Prism statistical software package,
version 3.0 (GraphPad Software Inc. 1994-1999). Statistical significance was accepted at
the 95% confidence interval. All values represented in figures and tables are mean ± SD.
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Table 2.1. List of qPCR primer sequences.
Primer

Sequence (5’  3’)

IFN-γ Forward

AGTTCGAGGTGAACAACCCACAG

IFN-γ Reverse

ATCAGCACCGACTCCTTTTCCG

TNF-α Forward

TTCGGGGTGATCGGTCCCAAC

TNF-α Reverse

TGGTGGTTTGCTACGACGTGG

ICAM-1 Forward

ACTGTGTATTCGTTCCCAGAGCG

ICAM-1 Reverse

TCATTCCCACGGAGCAGCAC

BID Forward

TGTCGGTCGGCAAACCTCTG

BID Reverse

GCCATTGCTGACCTCAGAGTCC

ERK-1 Forward

TACGGCATGGTCAGCTCAGC

ERK-1 Reverse

TCTCATGGCGGAATCCGAGC

ERK-2 Forward

GCCCATTGCTGAAGCACCATTC

ERK-2 Reverse

TCCTCTGAGCCCTTGTCCTGAC

GAPDH Forward

TCTTGTGCAGTGCCAGCCTC

GAPDH Reverse

GTCACAAGAGAAGGCAGCCCTGG
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2.4 Results
H2S improves transplant recipient survival after prolonged cold storage of renal grafts
Following RTx, we observed a significant increase in recipient survival rates in the H2Streated group compared to the UW animals (p = 0.0003). While no animals in the UW
group survived past day 5 (all but one died on post-transplant day 3), the H2S-treated
group exhibited nearly 80% survival after 14 days (Figure 2.1).
H2S gradually improves renal graft function after prolonged cold storage
Immediately following RTx, serum creatinine levels in the UW group were significantly
higher (545.4 µmol/L) versus Sham animals (57.5 µmol/L, p<0.05) (Figure 2.2). UW
animals died in an anuric state with increasing serum creatinine, whereas H2S treated
animals showed a marked decreased in serum creatinine levels from 334.2 µmol/L
towards baseline (Sham) by the second collection period and remained there until
sacrifice. Notably, one UW animal survived until day 5, whereupon its serum creatinine
was measured to be 353.6 µmol/L. One H2S treated animal was maintained to establish
long-term survival (creatinine 106.1 µmol/L at day 60).
H2S induces early diuresis and decrease in urine electrolyte levels and preserves renal
filtration capacity
H2S treated animals experienced significant diuresis (p<0.05) during the first two
collection periods (29.9 mL/24h and 15.8 mL/24h, respectively) compared to Sham
treated animals (5.3 mL/24h and 3.5 mL/24h, respectively) (Figure 2.3). Urine [Na+] and
[K+] levels of H2S treated animals were significantly lower (32.9 mmol/L and 79.3
mmol/L, respectively) than Sham (163.0 mmol/L and 371.3 mmol/L, respectively) during
the first collection period (p<0.05) but increased toward Sham levels during the later
collection periods (Table 2.2). Urinary protein levels and GFR were not significantly
different between the H2S and Sham treated groups.
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***p<0.001 vs UW
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Figure 2.1. H2S improves survival of renal transplant recipients after prolonged cold
storage of renal grafts. Survival rates of renal transplant recipients receiving donor
kidneys perfused and stored at 4 ºC for 24 hours in University of Wisconsin solution only
(UW group) or UW solution plus 150 µM NaHS (H2S group) as well as sham-operated
animals (Sham). UW (n=4), H2S (n=8), Sham (n=4). ***p<0.001 versus UW.
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H2S protects renal grafts from glomerular and tubular necrosis and apoptosis
Renal grafts underwent H&E and TUNEL staining to assess glomerular and tubular
necrosis and cellular apoptosis, respectively. H2S treated kidneys showed significantly
decreased (p<0.05) glomerular coagulative necrosis and tubular necrosis compared to
UW treated kidneys on both gross appearance and pathological scoring (Figure 2.4 A,
Figure 2.5). As well, H2S treated renal grafts exhibited markedly less DNA fragmentation
upon TUNEL staining (Figure 2.4 B,C) and significantly lower (p<0.05) apoptosis scores
upon pathological scoring (Figure 2.5) compared to UW treated grafts
H2S exhibits anti-inflammatory and anti-apoptotic effects
Post-mortem grafts were immunohistochemically stained with antibodies against
neutrophil marker MPO and macrophage marker CD68 (Figure 2.6). UW treated grafts
exhibited significantly increased (p<0.05) numbers of both MPO-positive and CD68positive cells compared to Sham animals, while H2S treated grafts showed significantly
fewer (p<0.05) numbers of both cell types at both 3 to 5 days and at 14 days post Tx,
compared to UW (Figures 2.6 and 2.7). Grafts were also stained with antibodies against T
cell marker CD3, but no differences in T cell numbers were observed between treatment
groups (data not shown). In addition, expression of pro-inflammatory genes IFN-γ, TNFα and ICAM-1, pro-apoptotic gene BID and anti-apoptotic genes, ERK-1 and ERK-2
were analyzed for each treatment group. Expression of IFN-γ, TNF-α, ICAM-1 and BID
were markedly decreased in H2S treated grafts compared to UW, though these differences
did not reach statistical significance (p=0.069, Figure 2.8). Relative expression of ERK-2
was significantly increased (p<0.05) in the H2S group compared to UW, while ERK-1
expression was unchanged between groups (Figure 2.8).
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Figure 2.2. H2S improves renal graft function after prolonged cold storage of renal
grafts. Serum creatinine levels of renal transplant recipients after receiving donor
kidneys perfused and stored at 4 ºC for 24 hours in University of Wisconsin solution only
(UW group) or UW solution plus 150 µM NaHS (H2S group) as well as sham-operated
animals (Sham group). Note: one control animal survived until day 5 and serum
creatinine was measured at 353.6 µmol/L. UW (n=4), H2S (n=8), Sham (n=4). Values are
mean ± SD. *p<0.05 versus Sham days 1 to 3. **p<0.05 versus H2S days 1 to 3.
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Figure 2.3. H2S supplementation induces diuresis following renal transplantation.
Urine output levels of renal transplant recipients after receiving donor kidneys perfused
and stored at 4 ºC for 24 hours in University of Wisconsin (UW) solution plus 150 µM
NaHS (H2S group) and sham-operated animals (Sham group). Urine outputs were
measured through use of metabolic cages. Note: UW only treated animals did not
produce any urine. Values are mean ± SD. *p<0.05 versus Sham.
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Figure 2.4. H2S mitigates cellular necrosis and apoptosis in renal grafts.
Representative micrographs of renal grafts perfused and stored at 4 ºC for 24 hours in
University of Wisconsin (UW) solution only (UW group) or UW solution plus 150 µM
NaHS (H2S group) as well as sham-operated animals (Sham group) obtained at time of
death or after 14 days. Grafts were stained with Hematoxylin and Eosin for glomerular
and tubular necrosis (40X magnification) and TUNEL showing staining of fragmented
DNA, a sign of cellular apoptosis (10X and 40X magnification).

lo
m

G
la

er
u
si
s

si
s

1.0

*

Ap
op
to
si
s

ec
ro

rN

ec
ro

Tu
bu
la
rN

Necrosis/Apoptosis
Score

43

2.5

Sham
UW
H2S

2.0
*p<0.05 vs UW

1.5

*
*

0.5

0.0

44

Figure 2.5. H2S is associated with decreased histological scores of renal graft
necrosis and apoptosis. Pathological necrosis and apoptosis scores of renal grafts renal
grafts perfused and stored at 4 ºC for 24 hours in University of Wisconsin (UW) solution
only (UW group) or UW solution plus 150 µM NaHS (H2S group) as well as shamoperated animals (Sham group) obtained at time of death (UW) or after 14 days (H2S).
Sections were scored by a blinded transplant pathologist and scores are out of 2 (0 =
normal, 0.5 = minimal necrosis, 1 = mild necrosis, 1.5 = moderate necrosis and 2 =
marked necrosis). UW (n=4), H2S (n=7), Sham (n=2). Values are mean ± SD. *p<0.05
versus UW.
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Figure 2.6. H2S decreases inflammatory infiltrate in renal grafts on post-operative
day 3-5. Immunohistochemical (IHC) staining of renal grafts perfused and stored at 4 ºC
for 24 hours in University of Wisconsin (UW) solution only (UW) or UW solution plus
150 µM NaHS (H2S) as well as sham-operated animals (Sham) obtained at time of death
or after 3 to 5 days. Images are representative pictures of negative staining control,
lacking primary antibody incubation and grafts stained with primary antibodies against
neutrophil marker MPO, and macrophage marker CD68. Grafts were also stained with
antibodies against T cell marker CD3 but no differences were found between groups.
Magnification for each image is 20X.
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Figure 2.7. Quantification of immunohistochemical staining of renal grafts. Median
cell counts of positively stained cells contained in renal grafts perfused and stored at 4 ºC
for 24 hours in University of Wisconsin (UW) solution only (UW) or UW solution plus
150 µM NaHS (H2S) as well as sham-operated animals (Sham) obtained at time of death
or after 3 to 5 days then stained with antibodies against neutrophil marker MPO, and
macrophage marker CD68. Sham (n=3), UW Day 3-5 (n=3), H2S Day 3-5 (n=3), H2S
Day 14 (n=3). Values are mean ± SD. *p<0.05 versus Sham, †p<0.05 vs. UW Day 3-5.
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Figure 2.8. H2S modulates renal graft expression of inflammatory and apoptotic
genes. Quantitative PCR analysis of renal graft homogenates for expression levels of proinflammatory genes IFN-γ, TNF-α and ICAM-1, pro-apoptotic gene BID and antiapoptotic genes ERK-1 and ERK-2. Genes were normalized against GAPDH and fold
change of gene expression were compared to sham animals. Renal grafts were perfused
and stored at 4 ºC for 24 hours in University of Wisconsin (UW) solution only (UW
group) (n=3) or UW solution plus 150 µM NaHS (H2S group) (n=2) and obtained at postoperative days 3 to 5. Values are mean log2 fold change ± SD. *p<0.05 versus UW day 3
to 5.
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2.5 Discussion
There has recently been a surge of evidence supporting the notion that H2S has many
important physiological functions. While H2S has been found to be protective against IRI
in several models of warm tissue ischemia, no work has yet been done to investigate the
effects of H2S in a model of transplantation-associated cold renal IRI. The current study
utilized the supplementation of organ preservation solution with H2S in an attempt to
characterize any potential protective effects of H2S against renal graft injury incurred by
transplantation-associated IRI. We demonstrate, for the first time, that H2S plays a
cytoprotective role against IRI in the context of renal transplantation, resulting in
increased graft function, shown by decreased serum creatinine levels, and recipient
survival compared to standard preservation solution-treated kidneys at extremes of cold
storage. As well, H2S protected renal grafts against necrosis, apoptosis and inflammation
normally incurred during prolonged cold IRI. Our model of renal transplantationassociated IRI incorporated an extreme (24-hour) period of cold (4°C) organ storage,
which local experience has shown to be associated with a survival rate of approximately
5% when stored in UW solution alone and is evidenced by the observation that no UW
animal in our study survived past post-operative day 5 17. A previous study describing the
protective effects of UW solution during murine renal graft preservation showed that rats
receiving kidneys stored in only UW solution for similarly extreme periods of cold
storage as our study had much greater survival than is reported for the UW treated group
in our study (Biguzas et al. 1990). The main reason for this discrepancy is that this initial
study was not a survival model as recipient rats were allowed to keep their contralateral
native kidney for 4 to 5 days post-autotransplantation. This method likely allowed the
contralateral kidney to compensate for any initial loss of function in the cold-stored
autograft to sustain the life of the rat during the critical early recovery period of the
transplanted kidney. Our objective is not to cast doubt on the protective capabilities of
UW solution, but rather to suggest novel methods of optimizing the beneficial effect of
UW in cold renal preservation in hopes that the supplementation of H2S to standard
preservation solutions may improve their overall protective effects, allowing use of donor
kidneys previously thought to be too damaged for transplantation.
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Previous studies have indicated that gasotransmitters can improve early renal function
and survival in animals subjected to warm renal IRI. Topical application of H2S and the
NO-donor molsidomine have independently been shown to ameliorate serum creatinine
levels in animals exposed to warm renal IRI induced by clamping of renal pedicles for 45
minutes and 60 minutes, respectively 25;27. As well, a number of studies have shown that
CO inhalation as well as application of carbon monoxide-releasing molecules (CORM)
can increase animal and graft survival after renal grafts have been subjected to
transplantation-associated IRI 16;17;28. Interestingly, the induction of a hibernation-like
hypometabolic state in non-hibernating animals by inhalation of H2S gas has been shown
to improve survival of animals subjected to whole body and warm renal ischemia 18;29;30.
Hosgood and Nicholson previously demonstrated that H2S improves porcine renal graft
function and mitigates IRI-associated oxidative renal damage 31. However, this study
involved an ex vivo DCD model of renal transplantation, which is not as physiologically
representative as the actual organ transplantation performed in our study nor does it take
into account any possible immunological factors on graft function and survival. No
studies to our knowledge have yet shown a positive association between H2S treatment
and early renal graft function and recipient survival using a clinically applicable model of
actual organ transplantation.
A clinically important observation from our study is that H2S increases renal graft and
animal survival even after an extreme period of cold ischemia, when UW solution alone
was not sufficient to preserve the graft organ. Rates of DGF are proportional to length of
cold IRI and translate to decreased long-term graft survival (5;6). This issue may be
increasingly important when transporting zero-HLA mismatched kidneys between distant
geographical regions. In fact, zero-HLA mismatched kidneys are more likely to be
exposed to longer cold-storage times which often negate any positive immunological
benefits to the recipient. 32. Also considering that 27.5% of all deceased donor kidneys
transplanted experience >22 hours of cold ischemia, 7 the negative effects of prolonged
cold ischemia on renal graft function and survival are a real clinical concern; the potential
future benefit of adding H2S to preservation solutions may, one day, present a potential
solution to this ongoing issue.
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To our knowledge, this is the first study to elucidate the effects of supplemental H2S on
renal physiology following renal transplantation. We observed that H2S treated renal
grafts experienced significant early diuresis, and diminished natriuresis and kaliuresis, all
of which normalized toward baseline, while UW treated grafts did not produce urine at
all during this period due to severe IRI induced tissue damage. H2S treatment has been
shown to decrease intrarenal resistance and increase renal blood flow in kidneys
following IRI 31;33. However, it is unlikely that the vasodilatory properties of H2S are the
mechanism by which H2S causes initial diuresis in renal grafts as we previously
determined that H2S has approximately a 12-hour half-life in UW solution (data not
shown) and diuresis continues long after all exogenous H2S is likely dissipated from the
kidney. The decrease in urine [Na+] and [K+] levels in H2S treated animals during the first
collection period corresponds with the observed initial diuresis, suggesting that the
increased excreted urine is more dilute and that the re-absorption mechanisms in the
proximal convoluted tubule and loop of Henle are functioning correctly in these renal
grafts. Urine protein levels did not differ significantly between H2S and Sham treated
animals, suggesting that the glomerular basement membrane remains intact in H2S treated
animals, as confirmed on pathological analysis. GFR was also not significantly different
between H2S and Sham groups, which, in conjunction with the observed rapid
normalization of serum creatinine levels toward baseline in H2S treated animals, suggests
that H2S preserves the glomerular architecture following prolonged cold IRI. Since the
medullary concentration gradient appears to remain intact in H2S treated renal grafts, it is
also plausible that H2S has an inhibitory effect on anti-diuretic hormone (ADH), causing
diuresis due to loss of free water via decreased water re-absorption in the distal
convoluted tubule.
Histological staining revealed that H2S treatment significantly decreased glomerular and
tubular necrosis and apoptosis compared to UW, which is likely a major mechanism by
which H2S improves graft function and animal survival. Although the effect of H2S in
decreasing apoptosis and necrosis of ischemic myocardial and renal tissues has been
reported, this effect has not been studied in a clinically relevant model of transplantationinduced IRI 25;30;34-36. The subsequent surge in inflammatory cytokines and activation of
immune cells following reperfusion is a significant mediator of necrotic and apoptotic
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tissue injury during IRI 37. In our study we observed decreased numbers of MPO-positive
neutrophils and CD68-positive macrophages present in H2S treated grafts compared to
UW, as well as down-regulation of pro-inflammatory genes IFN-γ, TNF-α and ICAM-1.
Considering that leukocytes are the major immune cells present in the inflammatory
portion of IRI, it likely that this anti-leukocyte effect of H2S is a major mechanism by
which it protects against renal graft necrosis and apoptosis during prolonged cold IRI and
preserves renal graft function and survival. While several studies point to the association
of higher tissue levels of H2S with increased potency of local and systemic inflammatory
responses 38-40, more recent analyses support the notion of an anti-inflammatory role for
H2S. Our results agree with many previous in vitro studies showing that H2S has antiinflammatory actions via reduction in activation of pro-inflammatory transcription factor
NF-κB and down-regulation of ICAM-1 expression leading to decreased neutrophil
activation, adherence and invasion, as well as directly interfering with cytotoxic actions
of neutrophils by interacting with neutrophil derived peroxynitrite (ONOO-) 36;41;42. A
likely explanation for the non-statistical significance achieved in our analysis of
inflammatory markers is likely due to the time frame of evaluation. Both groups were
evaluated at the same time point (3-5 days post-Tx), and as such, we are at the tail end of
the initial inflammatory response which showed an attenuated response in the H2S group.
We also observed that H2S treatment decreased expression of pro-apoptotic gene BID and
significantly mitigated the down-regulation in renal graft expression of the anti-apoptotic
gene ERK-2 associated with prolonged cold IRI, which may explain the decreased levels
of apoptosis in H2S renal grafts compared to UW treated observed upon TUNEL staining.
This observation also concurs with recent evidence suggesting that H2S may prevent
cellular apoptosis through interactions with apoptotic signaling pathways, such as
attenuating the reduction in the expression of pro-survival protein Bcl-2, reducing
phosphorylation of pro-apoptotic signalling molecules p38 MAPK and JNK1/2 complex
and causing cleavage of the major pro-apoptotic signalling protein caspase-3 36;43. Taken
together, these mechanisms of protection by H2S involving anti-inflammatory and antiapoptotic properties likely occur in concert and may be important drivers behind our
findings in vivo.
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Our study presents novel and clinically applicable data which demonstrate that H2S is
protective against cold IRI incurred during renal transplantation and improves both short
and long-term graft and renal tubular function and overall survival following prolonged
cold ischemic insult. Furthermore, these protective effects of H2S appear to be mediated
by anti-inflammatory and anti-apoptotic mechanisms. The supplemental nature of the
H2S to standard cold renal cryoplegia is highly clinically applicable as it offers a solution
to maximize organ function and survival only by its addition to standard preservation
solutions, which would not alter any established institutional protocols and eliminate
possible toxic side effects of systemic H2S treatment to the donor or recipient patient.
Although we did not observe any untoward behavioural effects in H2S treated animals, its
toxicity profile demands further work identifying the dose at which H2S provides optimal
protection against renal IRI. In addition, considering that 25% of kidney transplants
performed in the United States are from expanded criteria donor kidneys exposed to
prolonged cold ischemic times, developing more effective means of reducing IRI injury
during renal transplantation, with the potential to improve both short and long-term
allograft survival using such agents as H2S, are critical to the future of organ
transplantation.
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Overview: This chapter utilizes a more clinically applicable model of murine allogeneic
renal transplantation to demonstrate that addition of hydrogen sulfide to standard
University of Wisconsin (UW) preservation solution improves early graft function and
survival, limits acute renal allograft injury following cold storage and alters the allograft
transcriptome toward a proliferative/regenerative phenotype, but does not modulate the
progression of allograft rejection.
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3.1 Abstract
Ischemia-reperfusion injury (IRI) is unavoidable during organ transplantation and
prolonged IRI is detrimental to short- and long-term graft function and survival.
Hydrogen sulfide (H2S) is a recently characterized, endogenously produced gaseous
molecule with important physiological roles and has been shown to be cytoprotective
during tissue IRI. The current study aims to determine whether H2S can mitigate cold
renal IRI in the clinically relevant context of allogeneic RTx. Following bilateral native
nephrectomy, Lewis rats underwent RTx with kidneys from Brown Norway donor rats
that were flushed with either cold (4°C) standard University of Wisconsin (UW)
preservation solution (UW group) or cold UW + 150 µM NaHS (H2S group) solution and
stored for 6 hours at 4°C in the same solution. Recipient animals were monitored for a
period of 14 days, or until time of sacrifice, using metabolic cages to assess various
parameters of renal graft function. H2S treatment improved early allograft survival and
function and decreased early levels of necrosis, apoptosis and kidney injury molecule 1
(Kim-1) compared to UW. H2S treatment did not affect allograft rejection but did
modulate the early allograft transcriptome to decrease expression of renal injury,
coagulation and cellular stress response genes and increase expression of cellular
proliferation and Interferon-gamma (Ifn-γ) induced genes compared to UW. Our findings
are the first to show that H2S protects donor kidneys against cold IRI in the context of
allogeneic RTx and potentially represent a novel and cost-effective therapeutic solution
to mitigate IRI and improve the clinical outcomes of renal transplantation.
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3.2 Introduction
Ischemia-reperfusion injury (IRI) is an unavoidable consequence of organ transplantation
and is severely detrimental to renal graft function and survival 1. Prolonged periods of
cold ischemia during renal transplantation (RTx) have been widely associated with
increased rates of delayed graft function (DGF) and decreased long-term graft survival 2,
3

. In addition, to keep up with growing transplant wait lists, many transplant programs

accept grafts with extended periods of cold ischemic times, thus further contributing to
the overall tissue injury post-reperfusion. Therefore, it is not surprising that IRI continues
to be a major determining factor of the overall success of transplanted organs.
Gasotransmitters are a family of small, endogenously produced, gaseous molecules
whose anti-inflammatory, anti-oxidant and anti-apoptotic effects have led to their recent
investigation as novel therapeutics to mitigate tissue injury during IRI 4. These molecules
include nitric oxide (NO), carbon monoxide (CO) and, most recently, hydrogen sulfide
(H2S) 5. Hydrogen sulfide is endogenously produced by three major enzymes,
cystathionine-γ-lyase (CSE), cystathionine-β-synthase (CBS) and 3-mercaptopyruvate
sulfurtransferase (3-MST), and modulates many important physiological functions, such
as vasodilation and cellular signaling 6. H2S treatment has been shown to abrogate IRIassociated renal injury following both warm and cold ischemia and has been identified as
a potential therapy in improving RTx outcomes 7, 8.
We have previously shown that H2S treatment drastically improves survival and function
and decreases graft injury and expression of apoptotic and inflammatory markers during
syngeneic RTx following prolonged cold organ storage 9. While this study proved the
protective capacity of H2S against cold IRI associated with RTx, these findings are of
limited clinical value as the vast majority of human kidney transplants are allogeneic.
Allogeneic transplantation is complicated by enhancement of both the innate and
adaptive recipient immune response against allografts due to mismatched antigens
present on donor tissue, resulting in increased graft injury compared to syngeneic
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transplantation. Therefore, the current study investigates the potential of H2S to mitigate
renal IRI in a murine model of allogeneic RTx following cold organ storage. We
demonstrate for the first time that H2S treatment during cold storage protects allografts
from IRI during allogeneic RTx, improving early allograft function and survival, limiting
allograft injury and modulating the allograft transcriptome to promote allograft recovery
and potentially cellular regeneration.
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3.3 Materials and Methods
Experimental animals
Male Brown Norway (n=26) and Lewis rats (n=28) were purchased from Charles River
Canada and used at 300 – 350 grams and maintained at the University of Western Ontario
according to standard conditions. We utilized the fewest number of animals in our study to
firmly establish biological and statistical relevance in accordance with institutional Animal
Use Subcommittee regulations that stress and enforce a “reduce-reuse-recycle” philosophy
when conducting animal studies.
Surgical procedure and post-operative monitoring of rats
Allogeneic renal transplantation was performed using left kidneys from Brown Norway
(BN) rat donors and Lewis rat recipients, a model which elicits a robust recipient immune
response against donor tissue. Rats were randomized into treatment groups, anaesthetized
with ketamine (30 mg/kg) and maintained under anaesthesia with 1% isoflurane during
surgery. Using aseptic techniques, donor kidneys were procured and flushed using a 28G
angiocath with either cold (4 °C) University of Wisconsin (UW) preservation solution
(UW group, n=9) or cold UW plus H2S donor molecule (150 µM NaHS (SigmaAldrich®); H2S group, n=7) until venous effluent was clear. The chosen dose of NaHS is
within the therapeutic range demonstrated by previous studies to be protective against
warm and cold renal IRI 28,29. Grafts were subsequently placed in 50 mL of the same
perfusion solution and stored at 4 °C for 6 hours, which represents a moderate level of
clinical cold storage time. Following bilateral nephrectomy, recipient rats underwent
renal transplantation (RTx) with donor kidneys removed from cold storage and
transplanted orthotopically into the left renal fossa using 10-0 prolene suture as
previously described 10. Lewis sham operated rats (midline incision only; n=5) were also
followed to establish a baseline for survival, serum creatinine and allo-antibody binding
analysis. BN sham operated rats (n=3) were sacrificed at POD1-2 and used as a baseline
for allograft histology and RNA microarray analysis. After RTx, rats were monitored in
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metabolic cages to assess urine output, water intake, and urine and serum creatinine and
urinary physiological parameters for 14 days or until sacrifice. The time course of 14
days was chosen as the majority of animals that survive past 7-8 days post-transplant
were observed to fully recover acute renal function and have passed the acute time period
in which we were most interested. An additional subset of animals had allografts
removed pre-emptively at POD 1-2 (UW, n=2; H2S, n=4) and combined with allografts
from survival analysis animals sacrificed at either at POD 1-2 (UW, n=3) or POD 6-9
(UW, n=6; H2S, n=6) for further analysis. Half of the sagitally bi-valved kidney was
placed in formalin for histological analysis and the other half was stored at -80 °C for
subsequent RNA microarray analysis. All surgeries were performed by the same microsurgeon and the length of surgery for the recipient was approximately 2-3 hours for both
treatment groups. There was no difference in operative times between treatment groups.
Renal failure was assumed in animals sacrificed prematurely while exhibiting elevated
serum creatinine levels. At time of sacrifice surgical complications were ruled out as a
cause of death.
Serum and urine analysis
Serum and urine osmolality and creatinine levels were determined using the freezing
point depression method, performed on the Advanced Instruments Micro Osmometer,
and the enzymatic method, performed on the Roche Modular P instrument, respectively.
GFR (mL/min/kg) was calculated using the formula (UCrV/PCr), dividing by 1440
(minutes/24 hours) and finally dividing by animal weight (kg). Free water clearance
(mL/min/kg) was calculated using the formula (V – ((UOsm/POsm)V)) and dividing by
animal weight (kg).
Histological staining
Histological sections were stained with hematoxylin and eosin (H&E) and scored by a
blinded transplant pathologist to assess acute tubular necrosis (ATN) and tubulitis (Banff
97 working classification of renal allograft pathology). Terminal deoxynucleotidyl
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transferase dUTP nick end labelling (TUNEL) assay was used to assess the degree of
apoptosis present in renal allograft sections. Histological sections also underwent
immunohistochemical (IHC) staining with antibodies against renal biomarkers of injury
kidney injury molecule 1 (Kim-1; Aviva Systems Biology) and neutrophil gelatinaseassociated lipocalin (Ngal; Aviva Systems Biology). Sections were visualized with
secondary antibodies and DAB substrate chromogen using the Dako Envision System as
per manufacturer protocol.
Microscopic image analysis
Immunohistochemically stained and TUNEL sections were analyzed using a Nikon
Eclipse 90i digital light microscope and ImageJ software v 1.48 (National Institutes of
Health, Bethesda, MD). Background was subtracted from images and the colour
threshold (RGB) was adjusted uniformly to accentuate positively stained areas which
were then measured digitally.
Allo-antibody binding analysis
A heterozygous BN x Lewis rat B cell lymphoma cell line, TIB-120 (ATCC®), was used
for allo-antibody binding analysis as these cells express BN antigens similarly to donor
kidney cells. Cells were incubated with pooled normal rat serum (Life Technologies) to
block surface Fc receptors then washed and incubated with serum obtained from recipient
rats at POD 1-2 (Sham, n=3; UW, n=4; H2S, n=4) and at time of sacrifice (POD 6-9)
(Sham, n=3; UW, n=5; H2S, n=5). Cells were then stained with both anti-IgG-PE and
anti-IgM-FITC antibodies (Jackson Immunoresearch) and analyzed via flow cytometry
(FC 500, Beckman Coulter). Cells were also stained with 7-aminoactinomycin D (7AAD; BioLegend®) and only 7-AAD-negative cells were included in the final analysis.
Allograft RNA microarray analysis
RNA was isolated from whole renal allograft homogenates, containing equal portions of
cortex and medulla, from UW (n=3), H2S (n=3) and BN Sham (n=3) animals using
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TRIzol reagent (Life Technologies). All sample labeling and GeneChip processing was
performed at the London Regional Genomics Centre (Robarts Research Institute,
London, ON). RNA quality was assessed using the Agilent 2100 Bioanalyzer and the
RNA 6000 Nano kit (Caliper Life Sciences). Single stranded complimentary DNA
(sscDNA) was prepared from 200 ng of total RNA as per the Ambion WT Expression Kit
for Affymetrix GeneChip Whole Transcript WT Expression Arrays. All liquid handling
steps were performed by a GeneChip Fluidics Station 450 and GeneChips were scanned
with the GeneChip Scanner 3000 7G (Affymetrix) using Command Console v3.2.4.
Probe. Data were summarized to gene level data in Partek Genomics Suite v6.6 using the
RMA algorithm 11. Levels of gene expression in UW and H2S kidneys were normalized
to Sham experiments. Genes that were a minimum 2-fold up- or down-regulated
compared to Sham were selected for analysis and genes with the largest fold-change
difference between UW and H2S groups were reported. For a complete list of gene names
reported in our study, see Table 3.1.
Statistical analysis
Survival data were analyzed via Kaplan-Meier survival analysis, serum data were
analyzed via ordinary one-way ANOVA and all other data were analyzed via unpaired
one-way Student’s t-test, performed using the GraphPad Prism statistical software
package, version 6.0. Statistical significance was accepted at the 95% confidence
interval. All values represented in figures are median with and without interquartile range
and minimum and maximum values.
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Table 3.1. List of rat gene names and respective cellular functions.
Gene ID

Full Gene Name

Cellular Function

Kim-1
(Havcr1)

Kidney injury molecule 1 (Hepatitis
A virus cellular receptor 1)

Endogenous mediator of
efferocytosis; Renal biomarker
of injury

Ngal (Lcn2)

Neutrophil gelatinase associated
lipocalin (Lipocalin 2)

Innate immune defense; Renal
biomarker of injury

Fgb

Fibrinogen beta chain

Coagulation cascade mediator

Fga

Fibrinogen alpha chain

Coagulation cascade mediator

Fgg

Fibrinogen gamma chain

Coagulation cascade mediator

Kng1

Kininogen 1

Coagulation cascade mediator

Serpine1

Serpin peptidase inhibitor, clade E

Coagulation cascade mediator

Serpina3n

Serine (or cysteine) peptidase
inhibitor, clade A

Cellular response to
inflammation

Olr1

Oxidized low density lipoprotein
(lectin-like) receptor 1

Cellular regulation of
apoptosis

Adamts1

ADAM metallopeptidase with
thrombospondin type 1 motif

Cellular response to
inflammation

Timp1

TIMP metallopeptidase inhibitor 1

Cellular regulation of
apoptosis

Atf3

Activating transcription factor 3

Cellular response to oxidative
stress

Myc

Myelocytomatosis oncogene

Cellular response to oxidative
stress

Cdkn3

Cyclin-dependent kinase inhibitor 3

Cell cycle arrest at G1 mitotic
phase

Mki67

Antigen identified by monoclonal
antibody Ki-67

Nuclear protein; associated
with ribosomal RNA synthesis

Plk1

Polo-like kinase 1

Associated with sister
chromatid separation; G2/M
mitotic phase trigger

Top2a

Topoisomerase (DNA) II alpha

Promotion of chromosome
condensation, chromatid
separation
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LOC679994

Similar to histone 1, H2ai

Promotion of chromosome
condensation

Kif20a

Kinesin family member 20a

Induction of cytokinesis

Pttg1

Pituitary tumor-transforming gene 1

Anaphase-promoting complex
member

Ccnb1

Cyclin B1

Promotion of chromosome
condensation, spindle pole
assembly

Rrm2

Ribonucleotide reductase M2

DNA synthesis

Tpx2

TPX2, microtubule-associated,
homolog

Microtubule localisation to
spindle poles

Cdc20

Cell division cycle 20

Activation of anaphasepromoting complex;
Promotion of sister chromatid
separation

Prc1

Protein regulator of cytokinesis 1

Induction of cytokinesis

Casc5

Cancer susceptibility candidate 5

Promotion of microtubule
attachment to kinetochores

Cdk1

Cyclin-dependent kinase 1

Trigger for G1/S mitotic phase
entry

Ect2

Epithelial cell transforming sequence
2 oncogene

Induction of cytokinesis

Cdca3

Cell division cycle associated 3

Trigger for G2/M mitotic
phase entry

Cenpf

Centromere protein F

Promotion of centromerekinetochore complex

Ccnb2

Cyclin B2

Mediator of TGF-β cell cycle
control

Ccna2

Cyclin A2

Initiation of DNA synthesis

Pbk

PDZ binding kinase

Phosphorylation of p38 MAPK

Esco2

Establishment of sister chromatid
cohesion N-acetyltransferase

Establishment of sister
chromatid cohesion

Bub1

BUB1 mitotic checkpoint
serine/threonine kinase

Establishment of mitotic
spindle checkpoint

Kif4a

Kinesin family member 4A

Microtubule motor protein
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RGD1305184

Similar to cDNA sequence
BC023105

GTPase; role in IFN-γ induced
intracellular membrane
trafficking

MGC108823

Similar to interferon-inducible
GTPase

Role in IFN-γ induced
intracellular membrane
trafficking

Gbp5

Guanylate binding protein 5

Role in IFN-γ induced cellular
immunity

Ifi47

Interferon gamma inducible protein
47

Role in IFN-γ induced cellular
immunity

Psmb9

Proteasome (prosome, macropain)
subunit, beta type, 9

IFN-γ induced processing of
class I MHC peptides

Gbp2

Guanylate binding protein 2,
interferon-inducible

GTPase; role in IFN-γ induced
intracellular membrane
trafficking

Irgm

Immunity-related GTPase family, M

IFN-γ induced regulation of
autophagy

Cxcl9

Chemokine (C-X-C motif) ligand 9

IFN-γ induced proinflammatory chemokine;
recruitment of T cells

Cxcl11

Chemokine (C-X-C motif) ligand 11

IFN-γ induced proinflammatory chemokine;
recruitment of T cells

Cxcl10

Chemokine (C-X-C motif) ligand 10

IFN-γ induced proinflammatory chemokine;
recruitment of macrophages, T
cells, NK cells, dendritic cells
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3.4 Results
Hydrogen sulfide treatment improves early allograft survival and function.
Animals that received allografts treated with H2S during cold storage exhibited
significantly improved survival (p<0.01) compared to those receiving UW treated
allografts, particularly in the first seven post-operative days (POD) (Figure 3.1A). At
POD 8 the survival of both treatment groups declined dramatically though one H2S
animal reached the end of the time course (14 days) (Figure 3.1A). Serum creatinine
levels were used to assess allograft function rather than creatinine clearance as urine
could not be obtained from animals sacrificed at early time points. Allograft function
mirrored survival in that while UW animals exhibited significantly increased serum
creatinine levels (p<0.01) at POD 2 compared to Sham, H2S treated animals exhibited
markedly decreased serum creatinine levels that were not statistically different (p>0.05)
compared to Sham (Figure 3.1B). Serum creatinine levels in animals that survived until
POD 4 decreased towards baseline, though UW animals that were sacrificed on POD 4
exhibited markedly higher serum creatinine levels compared to H2S treated animals
(Figure 3.1B). By POD 6, serum creatinine levels increased dramatically in both
treatment groups compared to Sham as animals began to lose allografts (Figure 3.1B).
Urine was collected from animals that survived until at least POD 6 and urine
output:water intake ratio, glomerular filtration rate (GFR) and free water clearance were
determined to further assess allograft function. Both UW and H2S treated animals
exhibited near baseline (Sham) levels in all renal physiological parameters at POD 4,
which declined to critically low levels as allografts began to lose function (data not
shown).
Hydrogen sulfide treatment mitigates cold IRI-induced early allograft injury.
To determine the effect of H2S treatment on renal allograft injury, H&E sections were
scored for ATN, apoptosis was assessed via TUNEL staining and expression of the
important biomarkers of renal injury, Kim-1 and Ngal, were quantified via IHC staining.

73

100

S ham

A
S u r v iv a l ( % )

80

UW
H2S

60

40

20

**

0
0

2

4

6

8

10

12

14

800

**
*

**

S ham
UW

600

H2S

400

200

T im e (D a y s )

6

4

0
2

B

S e r u m [ C r e a t in in e ] ( u m o l/L )

T im e (D a y s )

74

Figure 3.1. H2S improves renal allograft survival and function following 6-hour cold
organ storage and allogeneic renal transplantation.
Survival rates (A) and serum creatinine levels (B) of renal transplant recipient rats
receiving donor kidneys stored in UW only (UW; n=9) or UW + 150 µM NaHS (H2S;
n=7) for 6 hours at 4°C as well as sham-operated rats (Sham; n=5). *p<0.05 vs. Sham;
**p<0.01 vs. UW (survival graph) and vs. Sham (serum creatinine graph).
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UW treated allografts exhibited significantly elevated (p<0.05) acute tubular necrosis
(ATN) scores compared to Sham at POD 1-2, while H2S treated allografts exhibited
markedly decreased scores compared to UW, which were not significantly different
compared to Sham (Figure 3.2A,B). In addition, UW treated allografts showed markedly
increased levels of apoptotic cells and Kim-1 staining at POD 1-2 compared to Sham,
while H2S treated allografts exhibited significantly fewer (p<0.05) apoptotic cells and
markedly decreased Kim-1 expression compared to UW at POD 1-2 (Figures 3.2C,D and
3.3A,B). Renal Ngal staining was not significantly different between H2S and UW treated
allografts (Figure 3.3C,D). All markers of renal injury were highly elevated in both
treatment groups by POD 6-9 as animals began to lose allografts (Figures 3.2A,B,C,D
and 3.3A,B,C,D).
Hydrogen sulfide does not modulate progression of allograft rejection.
While it was thought that H2S-mediated reduction of renal allograft injury during cold
storage could possibly slow the response of recipient innate immune cells to damaged
donor tissue and thus delay adaptive immune-mediated allograft rejection, this notion was
ultimately disproven. UW treated allografts exhibited elevated levels of tubulitis
compared to Sham at POD 1-2, while H2S treated allografts exhibited decreased tubulitis
levels compared to UW at POD 1-2 (Figure 3.4A). In addition, TIB-120 cells incubated
with serum from both UW and H2S treated animals at POD 1-2 exhibited low levels of
allo-antibody binding that were not significantly different compared to cells incubated
with naïve (Sham) serum (Figure 3.4B,C). Both parameters of allograft rejection
significantly increased (p<0.05) to high levels in both treatment groups compared to
Sham by POD 6-9 as animals began to lose allografts (Figure 3.4A,B,C).
Hydrogen sulfide modulates the early allograft transcriptome.
H2S treatment markedly altered allograft transcriptomes (Figures 3.5A,B and 3.7A,B). Of
all genes either upregulated or downregulated at least 2-fold compared to Sham, the most
highly upregulated genes in each treatment group were selected for study and genes with
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Figure 3.2. H2S mitigates renal allograft necrosis and apoptosis following 6-hour
cold organ storage and allogeneic renal transplantation.
Representative images (10X magnification) of renal allograft sections stored in UW only
or UW + 150 µM NaHS for 6 hours at 4°C as well as sham-operated rats stained with
Hematoxlyin & Eosin (A) to assess acute tubular necrosis (ATN) and TUNEL (C) to
assess apoptosis (brown staining denotes fragmented DNA). (B) H&E sections were
assigned ATN scores out of 5 (0 = 0% graft ATN, 1 = <10% graft ATN, 2 = 11-25%
graft ATN, 3 = 26-45% graft ATN, 4 = 46-75% graft ATN, 5 = >75% graft ATN). (D)
Digital analysis of absolute numbers of apoptotic cells in TUNEL sections. Colour
threshold limits are as follows as follows (Lower (bytes)/Upper (bytes)): Red 0/245,
Green 0/115, Blue 0/105. Sections were obtained at POD 1-2 (Sham, n=3; UW, n=5;
H2S, n=4) and POD 6-9 (UW, n=6; H2S, n=6). Note: one H2S animal included in the
POD6-9 groups survived until POD18. *p<0.05.
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the greatest difference in fold-change expression vs. Sham were reported. Expression of
Kim-1 and Ngal was highly upregulated in both treatment groups compared to Sham,
although H2S treatment significantly decreased (p<0.05) expression of these renal injury
markers (Figure 3.5A and 3.6A). The most highly upregulated genes in UW treated
allografts were those involved in the coagulation cascade, such as fibrinogen (Fg) and
kininogen (Kng), and serpin peptidase inhibitor clade E1 (SerpinE1), as well as those
involved in the cellular response to stress, including the serpin peptidase inhibitor clade
A3 (SerpinA3), ADAM metallopeptidase with thrombospondin type 1 (Adamts1),
oxidized LDL receptor 1 (Olr1), TIMP metalloproteinase inhibitor 1 (Timp1), Activating
transcription factor 3 (Atf3) and Myelocytomatosis oncogene (Myc) (Figure 3.5A,B and
3.6B,C). H2S treated allografts exhibited decreased expression of these coagulation and
stress response genes compared to UW allografts, with SerpinA3, Adamts1, Olr1 and
Timp1 expression exhibiting statistically significant decreases (p<0.05) (Figure 3.6B,C).
The most highly upregulated genes in H2S treated allografts were those involved in
cellular proliferation, including genes involved in DNA synthesis, cytoskeleton
arrangement and cytokinesis, as well as a number of Interferon-gamma (Ifn-γ) induced
genes including chemokine (C-X-C motif) ligand 9 (Cxcl9), Cxcl10 and Cxcl11 among
others (Figure 3.7A,B and 3.8A,B). UW treated allografts exhibited markedly decreased
expression of all cellular proliferation and Ifn-γ induced genes, with some statistically
significant decreases (p<0.05), compared to H2S (Figure 3.7A,B).
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Figure 3.3. H2S mitigates renal allograft expression of KIM-1 but not NGAL
following 6-hour cold organ storage and allogeneic renal transplantation.
Representative images (10X magnification) of renal allograft sections stored in UW only
(UW) or UW + 150 µM NaHS (H2S) for 6 hours at 4°C as well as sham-operated rats
(Sham) immunohistochemically stained for renal biomarkers of injury kidney injury
molecule 1 (KIM-1) (A) and neutrophil gelatinase associated lipocalin (NGAL) (C)
indicated by brown staining. (B and D) Digital analysis of % area of sections positive for
KIM-1 and NGAL, respectively. Colour threshold limits for each stain are as follows
(Lower (bytes)/Upper (bytes)): KIM-1 - Red 0/255, Green 0/135, Blue 0/135; NGAL Red 0/255, Green 0/135, Blue 0/135. Sections were obtained at POD 1-2 (Sham, n=3;
UW, n=5; H2S, n=4) and POD 6-9 (UW, n=6; H2S, n=6). Note: one H2S animal included
in the POD 6-9 group survived until POD18. *p<0.05.
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Figure 3.4. H2S does not modulate allograft rejection following 6-hour cold organ
storage and allogeneic renal transplantation.
(A) Tubulitis scores of renal allograft sections stored in UW only (UW) or UW + 150 µM
NaHS (H2S) for 6 hours at 4°C as well as sham-operated rats (Sham). Tubulitis scores
were out of 3 (0 = No mononuclear cells in tubules, 1 = Foci with 1 to 4 cells/tubular
cross section, 2 = 5 to 10 cells/tubular cross section, 3 = >10 cells/tubular cross section).
Sections were obtained at POD 1-2 (Sham, n=3; UW, n=5; H2S, n=4) and POD 6-9 (UW,
n=6; H2S, n=6). (B) Representative IgM/IgG binding on TIB-120 cells incubated with
either (i) no recipient serum, (ii) recipient serum with low allo-antibody levels or (iii)
recipient serum with high allo-antibody levels. (C) Quantification of % of cells bound by
allo-antibodies following incubation with serum from recipient rats at POD 1-2 (Sham,
n=3; UW, n=4; H2S, n=4) POD 6-9 ((Sham, n=3; UW, n=5; H2S, n=5). These data are
representative of two independent experiments. Note: one H2S animal included in the
POD6-9 groups survived until POD18. *p<0.05.
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Figure 3.5. H2S modulates allograft expression of renal injury/stress response and
coagulation genes following 6-hour cold organ storage and allogeneic renal
transplantation.
Heat map of genes involved in renal injury/stress response (A) and coagulation (B)
upregulated or downregulated at least 2-fold in renal allografts stored in UW only (UW;
n=3) or UW + 150 µM NaHS (H2S; n=3) for 6 hours at 4°C compared to sham-operated
rats (Sham; n=3). Gene expression was determined via RNA microarray analysis using
Affymetrix Rat Gene 1.0 ST arrays with RNA isolated from whole renal allograft
homogenates obtained at POD 1-2.
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Figure 3.6. H2S decreases allograft mRNA expression of renal injury biomarker,
coagulation and stress response genes following 6-hour cold organ storage and
allogeneic renal transplantation.
Fold change expression of genes involved in renal injury, coagulation and cellular stress
response in renal allografts stored in UW only (UW; n=3) or UW + 150 µM NaHS (H2S;
n=3) for 6 hours at 4°C compared to sham-operated rats (Sham; n=3). Gene expression
was determined via RNA microarray analysis using Affymetrix Rat Gene 1.0 ST arrays
with RNA isolated from whole renal allograft homogenates obtained at POD 1-2.
*p<0.05; **p<0.01.
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Figure 3.7. H2S modulates allograft expression of renal injury/stress response and
coagulation genes following 6-hour cold organ storage and allogeneic renal
transplantation.
Heat map of genes involved in cellular proliferation (A) and response to IFN-γ signaling
(B) upregulated or downregulated at least 2-fold in renal allografts stored in UW only
(UW; n=3) or UW + 150 µM NaHS (H2S; n=3) for 6 hours at 4°C compared to shamoperated rats (Sham; n=3). Gene expression was determined via RNA microarray
analysis using Affymetrix Rat Gene 1.0 ST arrays with RNA isolated from whole renal
allograft homogenates obtained at POD 1-2.
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Figure 3.8. H2S increases allograft mRNA expression of cellular proliferation and
IFN-γ induced genes following 6-hour cold organ storage and allogeneic renal
transplantation.
Fold change expression of genes involved in cellular proliferation and cellular response
to IFN-γ signaling in renal allografts stored in UW only (UW; n=3) or UW + 150 µM
NaHS (H2S; n=3) for 6 hours at 4°C compared to sham-operated rats (Sham; n=3). Gene
expression was determined via RNA microarray analysis using Affymetrix Rat Gene 1.0
ST arrays with RNA isolated from whole renal allograft homogenates obtained at POD 12. *p<0.05; **p<0.01.
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3.5 Discussion
Although research on the role of H2S in biology and medicine has been rapidly expanding
12

, investigation of the potential protective effects of H2S treatment against cold IRI

during RTx is limited 8. Considering that the majority of clinical renal transplantation is
allogeneic, previous studies investigating the protective effects of H2S during syngeneic
renal transplantation may have limited clinical impact. The current study utilizes a more
clinically relevant model of allogeneic RTx to demonstrate that H2S treatment during
cold (4°C) organ storage protects renal allografts against IRI, improving early allograft
function and survival and mitigating cold IRI-induced injury. While most animals in both
treatment groups eventually lost allografts due to suspected rejection, it is expected that
the acute protection of renal grafts provided by H2S (compared to UW alone) during cold
storage would translate to improved long-term allograft function and survival in
conjunction with immunosuppressive therapy. Urinary parameters of allograft function
were the same regardless of treatment, however H2S treatment prolonged the life of the
allograft such that 100% of H2S treated animals survived for urine to be collected on
POD 6, compared to only 40% of UW treated animals.
H2S treatment significantly reduced early allograft ATN and apoptosis compared to UW,
as was shown in previous studies 13, 14. We also noted that UW treated allografts
exhibited increased expression of Olr1 and Timp1 mRNA, two stress response genes
involved in apoptotic pathway regulation, compared to H2S at POD 1-2. However, it is
unclear whether H2S directly influences allograft apoptotic signaling pathways. Further
immunohistochemical analysis of renal allograft injury showed that H2S reduced
expression of Kim-1, but not Ngal, two important biomarkers that provide a more
sensitive assessment of early renal injury compared to ATN and apoptosis 15-17. Allograft
microarray analysis showed significantly decreased expression of both Kim-1 and Ngal
mRNA in H2S treated allografts compared to UW, contrasting with histological
observations. This discrepancy may be attributable to inadequate time for the modulation
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of Ngal transcription to manifest as decreased protein translation prior to analysis or due
to secretion of Ngal into urine by renal parenchymal cells.
To determine whether the initial protective effects of H2S also led to delayed progression
of allograft rejection, renal allografts were assessed for T-cell mediated rejection via
histological scoring for tubulitis and antibody-mediated rejection via allo-antibody
binding analysis. Based on these analyses, allografts in both treatment groups did not
exhibit any appreciable amount of rejection until POD 6-9. Importantly, there was no
significant difference in the patterns of allograft rejection in both H2S and UW treated
allografts, indicating that H2S treatment improves early survival by mitigating initial
allograft injury associated with cold IRI and does not modulate the recipient immune
response. Actually, H2S treated kidneys in our study exhibited greatly increased levels of
Ifn-γ inducible response and regulatory genes, including the monokine induced by
gamma interferon (MIG) family of pro-inflammatory chemokines, Cxcl-9, Cxcl-10 and
Cxcl-11. While this increased state of Ifn-γ-induced inflammation would seem at odds
with the observed protective benefits of H2S against renal IRI, a number of studies have
shown that Ifn-γ prevents allograft thrombosis, congestion and necrosis in the early posttransplant period while still promoting inflammatory cell infiltration 18-20. Alternately,
UW treated allografts exhibited increased expression of proteinase inhibitors involved in
the cellular stress response to inflammation, SerpinA3 and Adamts1, suggesting that H2S
diminishes other inflammatory pathways detrimental to early allograft function and
survival. Additionally, H2S treated allografts exhibited decreased expression of the
oxidative stress response genes Atf3 and Myc, indicating that H2S reduced allograft
oxidative stress. Modulation of inflammation and oxidative stress may play an important
role in H2S-mediated mitigation of renal IRI during transplantation.
Unexpectedly, the most highly upregulated genes in H2S treated allografts were a
multitude of cellular proliferation genes. These data suggest that H2S promotes tissue
regeneration, speeding recovery of renal function in the early post-transplant period. It
has been previously noted that H2S plays a complex role in the regulation of cell growth,
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can promote both cellular proliferation and cell cycle arrest and can promote wound
healing following various injurious stimuli 21-24. Interestingly, UW treated allografts also
exhibited marked upregulation of genes involved in the coagulation cascade compared to
H2S treated allografts. Renal thrombotic microangiopathy is a potential complication
during transplantation and is associated with impaired and long-term graft function and
survival 25. It has been recently demonstrated that H2S may play a role in regulating the
coagulation cascade by inhibiting platelet aggregation, potentially preventing the
formation of thrombi 26, 27. Thus, promotion of tissue regeneration and maintenance of
renal blood flow could be important mediators of the ability of H2S to improve graft
function following transplantation.
In conclusion, H2S treatment during cold storage effectively mitigates renal IRI
associated with allogeneic RTx, improving allograft function and survival and decreasing
allograft injury. To our knowledge, these data are the first to demonstrate the protective
effect of H2S against cold renal IRI in the context of allogeneic RTx. Transcriptome
analysis of renal allografts early in the post-transplant period has identified modulation of
apoptotic, Ifn-γ-mediated inflammatory and oxidative stress pathways, induction of
cellular proliferative processes and inhibition of the coagulation cascade as potential
mechanisms by which H2S speeds recovery of renal allografts following allogeneic RTx.
Overall, these data further strengthen the evidence for the potential therapeutic use of H2S
to improve preservation of donor kidneys to ultimately improve the clinical outcomes of
renal transplant recipients.
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Chapter 4

4 Hydrogen sulfide protects renal grafts against prolonged
cold ischemia-reperfusion injury via specific mitochondrial
actions
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Overview: This chapter characterizes the ability of H2S treatment to mitigate cold renal
IRI in our most injurious model of renal transplantation incorporating both prolonged
cold storage and the increased inflammatory response during allogeneic transplantation.
As well, this study identifies mitochondria as a primary target of action for H2S during
IRI, as targeting H2S release to mitochondria during hypoxic/ischemic injury vastly
improves the potency of its protective effects both in vitro and in vivo.
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4.1 Abstract
Organ procurement is inherently associated with ischemia-reperfusion injury (IRI),
resulting from loss and subsequent restoration of blood flow and leading to increased
rates of delayed graft function, acute graft rejection and early graft loss. Treatment of
donor organs with endogenously produced gasotransmitters such as hydrogen sulfide
(H2S) during preservation is a novel method for limiting IRI during cold organ storage.
The current study characterizes the protective effects of H2S during prolonged cold (4ºC)
organ storage in the context of allogeneic renal transplantation (RTx) and identifies the
mitochondrial actions of H2S to be sufficient for renoprotection during cold IRI.
Bilaterally nephrectomized recipient Lewis rats were transplanted with kidneys from
Brown Norway donor rats following 24 hours of cold storage in either standard
University of Wisconsin solution (UW group) or UW + 150 µM NaHS (H2S group).
Sham animals (midline incision only) were also included and animals were followed for
14 days to monitor graft function and survival and histological parameters of renal injury.
Rat renal epithelial cells (NRK-52E) were treated with either a non-specific H2S donor
(GYY4137) or a mitochondrial-targeted H2S donor (AP39) and exposed to in vitro cold
hypoxia/hypercapnia and re-oxygenation (H/R) injury. Lewis donor kidneys were also
stored at 4 ºC for 24 hours in either UW or UW + 200 nM AP39, then transplanted into
syngeneic recipient rats to assess graft function and survival. Donor allografts treated
with H2S during prolonged cold storage exhibited decreased necrotic/apoptotic injury and
improved graft function and survival following RTx. Treatment of cells with AP39
during in vitro cold H/R injury improved cellular viability, decreased ROS production
and maintained mitochondrial membrane permeability compared to similar levels of
GYY4137. AP39 also increased graft function and survival following prolonged cold
storage and syngeneic RTx compared to UW alone. H2S treatment during cold organ
storage appears to prevent graft injury through specific mitochondrial actions and could
represent a novel therapeutic strategy to minimize the detrimental effects of prolonged
cold IRI during clinical RTx and improve transplant patient outcomes.
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4.2 Introduction
Organ procurement is inherently associated with ischemia-reperfusion injury (IRI),
resulting from loss and subsequent restoration of blood flow, which leads to increased
rates of delayed graft function, acute graft rejection and early graft loss 1,2. Current
methods of limiting IRI during renal transplantation involve cold storage of kidneys in
preservation solution during the peri-transplant period 3. However, these strategies have
been maximized and prolonged periods (>24 hours) of cold IRI are still associated with
increased rates of acute tubular necrosis (ATN), delayed graft function and decreased
graft survival 4-9. While there are many components to the pathophysiology of IRI,
including reactive oxygen species (ROS) production, inflammation and induction of
cellular apoptotic pathways, it has been well established that mitochondrial damage and
subsequent dysfunction is a key mediator of these injurious pathways 10. During
ischemia, ATP depletion causes inhibition of mitochondrial Na+/K+ ion channels,
resulting in increased mitochondrial inner membrane permeability, influx of Ca2+ ions
and subsequent swelling of mitochondria. In addition, prolonged periods of ischemia can
permanently damage complexes in the electron transport chain (ETC), which are then
prone to electron leak and produce a burst of ROS as oxygen floods cells upon
reperfusion. Reactive oxygen species are also produced in mitochondria as a result of
conversion of xanthine dehydrogenase, a constitutively expressed mitochondrial enzyme,
to xanthine oxidase during ischemia. Xanthine oxidase then converts hypoxanthine to
uric acid, producing superoxide as a byproduct. High levels of mitochondrial ROS
production combined with Ca2+-induced mitochondrial swelling result in severe damage
of mitochondrial membranes and formation of mitochondrial permeability transition
pores (MPTP), releasing pro-apoptotic factors, cytochrome c and apoptosis inducing
factor (Apaf), which then activate the caspase 9/3 apoptotic signaling cascade, initiating
cellular apoptosis 11.
Treatment of donor kidneys with gasotransmitters has recently been identified as a
potential therapeutic strategy to limit IRI during renal transplantation 12. Gasotransmitters
are endogenously produced gaseous molecules that share similar physical and chemical
characteristics. This family of molecules currently includes nitric oxide (NO), carbon
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monoxide (CO) and the most recently characterized member, hydrogen sulfide (H2S) 13.
Hydrogen sulfide is an endogenously produced gaseous molecule derived from cysteine
by the actions of three major cellular enzymes, cystathionine β-synthase (CBS),
cystathionine γ-lyase (CSE) and 3-mercaptopyruvate sulfurtransferase (3-MST) 14. In
addition to playing important physiological roles in cellular signaling and vasodilation
15,16

, H2S has been found to exhibit anti-oxidant, anti-inflammatory and anti-apoptotic

effects that protect kidneys during warm ischemic injury 17-20. Addition of H2S to organ
preservation solution during cold organ storage is a promising therapeutic strategy to
reduce graft injury associated with prolonged cold IRI.
We have previously shown that treatment of renal grafts with H2S mitigates IRIassociated graft injury and improves early graft function and survival in murine models
of syngeneic renal transplantation (RTx) following prolonged (24-hour) cold storage 21
and allogeneic RTx following moderate (6-hour) cold storage 22. Allogeneic models of
RTx make use of a genetically dissimilar donor and recipient, which results in a more
complex inflammatory component of tissue injury than syngeneic models due to the
robust recipient immunological response against donor antigens. Our two previous
models investigating the protective effects of H2S during RTx have only involved one of
either prolonged cold IRI or allogeneic inflammatory response to donor grafts. Therefore,
to determine whether H2S can mitigate IRI in the most unfavourable clinical
circumstances, the current study investigates the protective effects of H2S in the context
of allogeneic RTx following prolonged (24-hour) cold organ storage. In addition, it has
recently been identified that H2S may exert protective effects by translocating to
mitochondria during hypoxia/ischemia, where it prevents oxidative damage and preserves
mitochondrial membrane integrity 23-25. However, this potential mechanism by which H2S
confers protection against IRI has not been well explored in a relevant model of RTx.
Considering the strong influence mitochondria exert over cellular apoptotic pathways,
mitochondrial-targeting of H2S release could represent a potent strategy for reducing the
impact of IRI during renal transplantation. Consequently, the current study also aims to
characterize renoprotective effects of H2S specific to mitochondria during in vitro
hypoxic injury and in vivo cold IRI.
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4.3 Materials and Methods
Experimental animals
Male Brown Norway (n=56) and Lewis rats (n=52) were purchased from Charles River
Canada and used at 300 – 350 grams and maintained at the University of Western Ontario
according to standard conditions. We utilized the fewest number of animals in our study
to firmly establish biological and statistical relevance in accordance with institutional
Animal Use Subcommittee regulations.
Allogeneic renal transplant surgical procedure and post-operative monitoring of rats
Allogeneic renal transplantation was performed using left kidneys from Brown Norway
(BN) rat donors and Lewis rat recipients, a model which elicits a robust recipient immune
response against donor tissue. Rats were randomized into treatment groups, anaesthetized
with ketamine (30 mg/kg) and maintained under anaesthesia with 1% isoflurane during
surgery. Using aseptic techniques, donor kidneys were procured and flushed using a 28G
angiocath with either cold (4 °C) University of Wisconsin (UW) preservation solution
(UW group, n=8) or cold UW plus H2S donor molecule (150 µM NaHS (SigmaAldrich®); H2S group, n=8) until venous effluent was clear. The chosen dose of NaHS is
within the therapeutic range demonstrated by previous studies to be protective against
warm and cold renal IRI 17,40. Grafts were subsequently placed in 50 mL of the same
perfusion solution and stored at 4 °C for 24 hours, which represents an extreme period of
clinical cold storage time. Following bilateral nephrectomy, recipient rats underwent
renal transplantation (RTx) with donor kidneys removed from cold storage and
transplanted orthotopically into the left renal fossa using 10-0 prolene suture as
previously described 26. Lewis sham operated rats (midline incision only; n=5) were also
followed to establish a baseline for survival, serum creatinine and histological analysis.
After RTx, rats were monitored for a period of 14 days or until sacrifice to assess survival
ratios and serum creatinine levels, a surrogate marker of renal function. The time course
of 14 days was chosen as the majority of animals that survive past 7-8 days posttransplant were observed to fully recover acute renal function and have passed the acute
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time period in which we were most interested. Serum creatinine levels were determined
using the enzymatic method performed on the Roche Modular P instrument. An
additional subset of animals in the H2S group had allografts removed pre-emptively at
POD 2 (n=5) for comparison of histological analysis to UW animals that were sacrificed
at this time point. Additionally, donor kidneys in each treatment group (n=8 per group)
were obtained following cold storage, but prior to transplantation, to assess the protective
effects of H2S immediately following cold storage. Donor kidneys obtained prior to cold
storage were used as a baseline for this analysis (Pre-storage group; n=8). Following 24hour cold storage, donor kidneys were perfused with 10 mL of 5 µM Ethidium
Homodimer (EthD-1) at a rate of 1 mL/min and subsequently washed by perfusion with 5
mL phosphate-buffered saline (PBS) at a rate of 1mL/min. EthD-1 fluoresces once bound
to double-stranded DNA and is a marker of cellular necrosis as it can only enter cells if
the plasma membrane is compromised. In each arm of the study, renal grafts obtained at
time of sacrifice were sagitally bi-valved placed in formalin for histological analysis. All
surgeries were performed by the same micro-surgeon and the length of surgery for the
recipient was approximately 2-3 hours for both treatment groups. There was no
difference in operative times between treatment groups. Renal failure was assumed in
animals sacrificed prematurely while exhibiting elevated serum creatinine levels. At time
of sacrifice surgical complications were ruled out as a cause of death.
Histological staining
Histological sections were stained with hematoxylin and eosin (H&E) and were assessed
for the presence of necrotic tubules that exhibit loss of nuclei and necrotic casts with a
background of congestion, then assigned a score for acute tubular necrosis (ATN) by a
blinded transplant pathologist (ATN scores out of 5; 0 = 0% graft ATN, 1 = <10% graft
ATN, 2 = 11-25% graft ATN, 3 = 26-45% graft ATN, 4 = 46-75% graft ATN, 5 = >75%
graft ATN). To approximate acute allograft rejection, H&E sections were also assigned
tubulitis (T), vasculitis (V) and mononuclear cell interstitial inflammation (I) scores
according to the Banff 97 working classification of renal allograft pathology 27. Scores
are out of 3 (T: 0 = No mononuclear cells in tubules, 1 = Foci with 1 to 4 cells/tubular
cross section, 2 = 5 to 10 cells/tubular cross section, 3 = >10 cells/tubular cross section;
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V: 0 = No arteritis, 1 = Mild-to-moderate arteritis in at least one arterial cross section, 2 =
Severe intimal arteritis with at least 25% luminal area lost in at least one arterial cross
section, 3 = Transmural arteritis and/or arterial fibrinoid change and medial smooth
muscle necrosis with lymphocytic infiltrate in vessel; I: 0 = No or trivial interstitial
inflammation (<10% of unscarred parenchyma), 1 = 10 to 25% of parenchyma inflamed,
2 = 26 to 50% of parenchyma inflamed, 3 = >50% of parenchyma inflamed). Terminal
deoxynucleotidyl transferase dUTP nick end labelling (TUNEL) assay was used to assess
the degree of apoptosis present in renal allograft sections. For EthD-1 analysis, kidneys
were sectioned, stained with the nuclear marker 4',6-diamidino-2-phenylindole (DAPI)
and analyzed via fluorescent microscopy.
Microscopic image analysis
TUNEL and EthD-1 sections were analyzed using a Nikon Eclipse 90i digital light
microscope and an Olympus IX83 Inverted Microscope, respectively. Five images were
analyzed per section for TUNEL and EthD-1 analysis and total (+) staining per field of
view was quantified by ImageJ software v 1.48 (National Institutes of Health, Bethesda,
MD). Background was subtracted from images and the colour threshold (RGB) was
adjusted uniformly to accentuate positively stained areas which were then measured
digitally.
In vitro model of renal epithelial cell hypoxia/hypercapnia and re-oxygenation.
Underlying mechanisms of protective effects of H2S during renal IRI were assessed using
an in vitro model of cold hypoxia/hypercapnia and warm re-oxygenation (H/R) injury
that mimics cellular conditions during in vivo cold IRI. Rat kidney epithelial cells (NRK52E cell line; ATCC) were cultured in DMEM + 5% fetal bovine serum (FBS) and 1%
Penicillin/Streptomycin at 37 ºC in room O2 and 5% CO2 prior to experimentation.
During experimentation, control cells were cultured in identical conditions to preexperimental cells, except culture media contained no phenol red as this substance can
exhibit confounding anti-oxidant effects. Experimental cells were treated with either PBS
or PBS plus varying concentrations of the non-specific H2S donor, GYY4137, or the
mitochondrial-targeted H2S donor, AP39. Cells were exposed to cold (12 ºC)
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hypoxia/hypercapnia (0.1% O2/15% CO2) for 24 hours, followed by replacement of
experimental media with control media (no phenol red) and re-oxygenation in conditions
identical to pre-experimental cells. Cellular ROS production was assessed via staining of
cells with 10 µM of Dihydrorhodamine 123 (DHR-123; Molecular ProbesTM) following
15 min re-oxygenation and mitochondrial membrane permeability was assessed via
staining of cells with 5 µM JC-1 dye (Molecular ProbesTM) following 18 hours reoxygenation. Following 24 hours re-oxygenation, cellular viability was assessed via
staining of a separate subset of cells with Annexin-V and 7-AAD, which assess cellular
apoptosis and necrosis, respectively. A separate a subset of cells were centrifuged and
frozen at -80 ºC for subsequent RNA/protein isolation following 24 hours reoxygenation. Cells were analyzed via flow cytometry using the Beckman-Coulter FC 500
flow cytometer.
In vivo model of prolonged cold organ storage and syngeneic renal transplantation.
To assess protective effects of AP39 against renal graft IRI, Lewis rats underwent
bilateral native nephrectomy and subsequent RTx with syngeneic donor kidneys flushed
with either University of Wisconsin preservation solution (UW group; n=7) or UW + 200
nM AP39 (AP39 group; n=7) and stored for 24 hours at 4°C in the same solution. The
200 nM dose of AP39 used for this in vivo study was demonstrated to be protective for
renal epithelial cells during in vitro cold H/R injury and is the dose closest to 1000-fold
less than the 150 µM NaHS used in our previous in vivo models of renal transplantation.
Sham surgeries (midline incision only; n=5) were also performed and animals were
monitored for 14 days to assess graft function and survival.
Statistical Analysis
Survival data were analyzed via Kaplan-Meier survival analysis, all other data were
analyzed via ordinary one-way ANOVA and Tukey’s post-hoc test performed using the
GraphPad Prism statistical software package, version 6.0. Statistical significance was
accepted at the 95% confidence interval. All values represented in figures are mean or
median with minimum and maximum values.
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4.4 Results
Hydrogen sulfide treatment improves early allograft survival and function.
Animals that received allografts treated with H2S during cold storage exhibited
significantly improved survival (p<0.01) compared to those receiving UW treated
allografts (Figure 4.1A). While UW treated animals exhibited only 50% survival at postoperative day (POD) 2 and 0% survival at POD 6, H2S treated animals exhibited 50%
survival at POD 7 and still maintained ~10% survival by the end of the time course (POD
14) (Figure 4.1A). H2S treatment markedly improved allograft function during the early
post-transplant period compared to UW treatment. Both UW animals exhibited
significantly increased serum creatinine levels (p<0.001) at POD 2 and POD 4 compared
to Sham (Figure 4.1B). However, while UW animals exhibited serum creatinine levels
that only increased until POD 6 (0% survival) H2S treated animals exhibited serum
creatinine levels that decreased toward baseline (Sham) until time of sacrifice (Figure
4.1B). Blood urea nitrogen (BUN) levels exhibited the same trends in each treatment
group as serum creatinine levels (data not shown).
Hydrogen sulfide mitigates donor kidney necrosis but does not affect allograft rejection.
Renal sections stained with TUNEL revealed that while UW treated allografts exhibited
significantly elevated (p<0.05) levels of apoptosis compared to Sham at POD 2-4,
apoptosis levels in H2S treated kidneys were not significantly different compared to Sham
at the same time point (Figure 4.2). In addition, H&E staining showed that H2S treated
allografts exhibited slightly decreased ATN scores at POD 2-4 compared to UW (Figure
4.3A). Staining of renal allografts with EthD-1 was utilized to provide a more sensitive
measure of tubular necrosis during cold storage, as it can visualize cellular necrosis
before gross morphological changes associated with necrosis can be identified with H&E
staining and can be quantified via fluorescent microscopic analysis. Donor kidneys
treated with only UW solution during cold storage exhibited significantly increased levels
of EthD-1 fluorescence (p<0.01) compared to pre-storage kidneys, while H2S treated
kidneys exhibited significantly decreased EthD-1 fluorescence (p<0.05) compared to UW
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Figure 4.1. H2S improves renal allograft survival and function following 24-hour
cold organ storage and allogeneic renal transplantation.
Survival rates (A) and serum creatinine levels (B) of renal transplant recipient Lewis rats
receiving donor Brown Norway kidneys perfused and stored in UW solution only (UW;
n=8) or UW solution plus 150 µM NaHS (H2S; n=8) for 24 hours at 4°C as well as shamoperated Lewis rats (Sham; n=5). Survival data analyzed via Kaplan-Meier survival
analysis and log rank test. Serum creatinine data analyzed via one-way ANOVA and
Tukey’s post-hoc test. Lines indicate mean serum creatinine. *p<0.05; **p<0.01;
***p<0.001.
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kidneys (Figure 4.4). This indicates that H2S treated kidneys accumulated fewer necrotic
cells compared to UW treated kidneys during prolonged cold storage. To determine
whether H2S improves allograft survival by altering the progression of graft rejection,
renal sections were scored for acute rejection using components of the Banff 97 working
classification of renal allograft pathology. H2S treated allografts exhibited significantly
increased (p<0.05) inflammation, tubulitis and vasculitis scores at POD 6-14 compared to
both UW and H2S kidneys at POD 2-4 (Figure 4.3B). Since scores >2 in these categories
indicate acute allograft rejection, this observation suggests that UW treated animals lose
grafts early in the time period due to renal failure, not rejection, and that H2S by itself
does not modulate allograft rejection.
Targeting of hydrogen sulfide to mitochondria increases potency of protective effects
1000-fold during in vitro cold renal H/R injury.
To assess whether mitochondria are important sites of action for H2S-mediated
cytoprotection, and whether targeting H2S to mitochondria during hypoxia can prevent
cellular processes associated with mitochondrial injury, an in vitro model of cold H/R
injury was developed. Two different slow-release H2S donor molecules were used to test
this theory in our model: the non-specific H2S donor, GYY4137, and AP39, which
contains a cationic triphenylphosphonium (TPP+) group that allows it specific
accumulation in the negatively charged environment of mitochondria, with little
accumulation in other subcellular organelles 28,29. NRK-52E cells treated with PBS during
in vitro cold H/R injury exhibited significantly decreased cellular viability (p<0.05)
compared to control (normoxic) cells. Treatment of cells with 200 nM and 400 nM of
AP39 during cold H/R injury significantly improved cellular viability (p<0.05) compared
to PBS-treated cells, to levels similar to control cells. Cells treated with 100 nM, 200 nM,
400 nM and 100 µM of GYY4137 during cold H/R injury exhibited cellular viability
levels that were significantly decreased (p<0.05) compared to cells treated with 400 nM
AP39 and were not significantly different compared to PBS-treated cells (Figure 4.5B,C).
Only cells treated with 400 uM GYY 4137 exhibited significantly improved cellular
viability (p<0.05) compared to PBS-treated cells (Figure 4.5C). As well, cells treated
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Figure 4.2. H2S mitigates renal allograft apoptosis following 24-hour cold organ
storage and allogeneic renal transplantation.
(A) Representative images (10X magnification) of renal allograft sections perfused and
stored in UW solution only (UW) or UW solution plus 150 µM NaHS (H2S) for 6 hours
at 4°C as well as sham-operated Brown Norway rats (Sham) stained with TUNEL
showing staining for fragmented DNA, a marker of cellular apoptosis. Arrows indicate
cells positive for staining of fragmented DNA. (B) Corresponding digital analysis of
absolute numbers of apoptotic cells in TUNEL sections. Background was subtracted from
images and the colour threshold (RGB) was adjusted uniformly for each section so that
only positively stained areas would be measured. Sections were obtained at POD 2-4
(Sham, n=3; UW, n=7; H2S, n=8) and POD 6-14 (UW, n=1; H2S, n=7). *p<0.05.
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with 400 nM AP39 during cold H/R injury exhibited significantly decreased (p<0.0001)
levels of ROS production, measured via DHR-123 staining, and significantly increased
(p<0.0001) mitochondrial membrane potential, measured via JC-1 staining, compared to
cells treated with either PBS, 400 nM GYY4137 or 400 µM GYY4137 treatments
(Figures 4.6 and 4.7).
Treatment of renal grafts with AP39 during cold storage improves graft function and
survival following syngeneic RTx.
To assess whether AP39 can also prevent prolonged cold IRI in vivo, we utilized the
same model of syngeneic renal transplantation as previously described 21, to limit
confounding effects of allogeneic transplantation during initial in vivo testing of AP39.
Animals that received renal grafts treated with AP39 during cold storage exhibited
significantly improved survival (p<0.01) compared to UW treated animals. Whereas UW
treated animals exhibited ~40% survival at POD 2 and ~15% survival from POD 5 to end
of time course (POD 14), AP39 treated animals exhibited 100% survival at POD 2 and
retained ~70% survival by end of time course. AP39 treatment also improved graft
function (Figure 4.8A). UW treated animals exhibited significantly increased serum
creatinine (p<0.05) compared to Sham at POD 1-3 that increased until time of sacrifice,
with only one UW treated animals recovering renal function by POD 14. Conversely,
AP39 treated animals exhibited serum creatinine levels that were elevated, but not
significantly different, compared to Sham at POD 1-3 (Figure 4.8B). Only two AP39
treated animals exhibited serum creatinine levels that increased until time of sacrifice,
while the remainder reached baseline serum creatinine levels by POD 4-6 (Figure 4.8B).
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Figure 4.3. H2S may mitigate renal allograft necrosis scores but does not modulate
acute allograft rejection following 24-hour cold organ storage and allogeneic renal
transplantation.
(A) Acute tubular necrosis (ATN) scores of renal allograft sections perfused and stored in
UW solution only (UW) or UW solution plus 150 µM NaHS (H2S) for 24 hours at 4°C as
well as sham-operated Brown Norway rats (Sham) stained with Hematoxlyin & Eosin.
Sections were assessed for the presence of necrotic tubules that exhibit loss of nuclei and
necrotic casts with a background of congestion and assigned a score for ATN out of 5, (0
= 0% graft ATN, 1 = <10% graft ATN, 2 = 11-25% graft ATN, 3 = 26-45% graft ATN, 4
= 46-75% graft ATN, 5 = >75% graft ATN) (B) Acute rejection scores of renal allograft
sections stained with H&E and scored for tubulitis, vasculitis and inflammation according
to the Banff 97 working classification of renal allograft pathology. Sections were scored
by a blinded transplant pathologist and tubulitis, vasculitis and inflammation scores were
out of 3. Sections were obtained at POD 2-4 (Sham, n=5; UW, n=7; H2S, n=7) and POD
6-14 (H2S, n=7). Lines indicate median pathological score. *p<0.05; **p<0.01;
****p<0.0001.
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Figure 4.4. H2S decreases renal allograft necrosis immediately following 24-hour
cold organ storage.
(A) Representative fluorescent microscopic images (40X magnification) of kidney
sections taken from donor Brown Norway kidneys perfused and stored in UW solution
only (UW; n=8) or UW solution plus 150 µM NaHS (H2S; n=8) for 24 hours at 4°C as
well as kidneys obtained prior to cold storage (Pre-storage; n=8). Kidneys were perfused
with 5 µM EthD-1 following cold storage and subsequently placed in formalin for
histological analysis. Sections were also stained with the nuclear marker DAPI. (B)
Digital quantification of EthD-1 fluorescence levels. Sections digitally quantified via
ImageJ analysis and values are mean EthD-1 fluorescence of 5 random fields of view
(20X magnification) taken per sample. Lines indicate mean EthD-1 fluorescence per
treatment group. *p<0.05, **p<0.01.
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Figure 4.5. Targeting of H2S release to mitochondria improves potency of protective
effects during in vitro cold hypoxia/hypercapnia and re-oxygenation (H/R) injury.
Cellular viability levels of rat kidney epithelial (NRK-52E; ATCC) cells following in
vitro cold H/R injury. Control cells were cultured in DMEM + 5% fetal bovine serum
(FBS) at 37 ºC in room O2 and 5% CO2. Experimental cells were treated with either
phosphate-buffered saline (PBS) alone or PBS plus varying concentrations of GYY4137
(non-specific H2S donor) or AP39 (mitochondrial-targeted H2S donor) and exposed to
cold (12 ºC) hypoxia/hypercapnia (0.1% O2/15% CO2) for 24 hours (n=5 per treatment
group). Cells were then re-oxygenated for 24 hours in conditions identical to control cells
and viability was assessed via flow cytometry using Annexin-V/7-AAD staining,
indicating apoptosis and necrosis, respectively. (A) Representative FACS plots of healthy
cells vs. injured cells. (B) Quantification of % viable (Annexin-V(-)/7-AAD(-)) cells
treated with either DMEM, PBS or PBS (+) 100-400 nM AP39 or GYY4137. (C)
Quantification of % viable (Annexin-V(-)/7-AAD(-)) cells treated with either DMEM,
PBS or PBS (+) 100-400 µM GYY4137. Bars indicate mean ± SEM. *p<0.05 vs.
DMEM, δ p<0.05 vs. PBS, ϕ p<0.05 vs. 400 nM AP39.
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Figure 4.6. AP39 is more potent at reducing ROS production during in vitro cold
hypoxia/hypercapnia and re-oxygenation (H/R) injury compared to GYY4137.
Levels of ROS production in rat kidney epithelial (NRK-52E; ATCC) cells following in
vitro cold H/R injury. Control cells were cultured in DMEM + 5% fetal bovine serum
(FBS) at 37 ºC in room O2 and 5% CO2. Experimental cells were treated with either
phosphate-buffered saline (PBS) alone or PBS (+) 400 nM or 400 µM GYY4137 (nonspecific H2S donor) or 400 nM AP39 (mitochondrial-targeted H2S donor) and exposed to
cold (12 ºC) hypoxia/hypercapnia (0.1% O2/15% CO2) for 24 hours (n=5 per treatment
group). Cells were then re-oxygenated for 15 min in conditions identical to control cells
and ROS production was assessed via flow cytometry using DHR-123 staining, which
becomes fluorescent when oxidized by ROS. (A) Representative FACS plots of DHR123 fluorescence in cells exposed to H/R injury. Quantification of (B) DHR-123 MFI and
(C) %DHR-123 (+) cells in each treatment group. Bars indicate mean ± SEM.
****p<0.0001.
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Figure 4.7. AP39 preserves mitochondrial membrane potential following in vitro
cold hypoxia/hypercapnia and re-oxygenation (H/R) injury.
JC-1 staining in rat kidney epithelial (NRK-52E; ATCC) cells following in vitro cold
H/R injury. Control cells were cultured in DMEM + 5% fetal bovine serum (FBS) at 37
ºC in room O2 and 5% CO2. Experimental cells were treated with either phosphatebuffered saline (PBS) alone or PBS (+) 400 nM or 400 µM GYY4137 (non-specific H2S
donor) or 400 nM AP39 (mitochondrial-targeted H2S donor) and exposed to cold (12 ºC)
hypoxia/hypercapnia (0.1% O2/15% CO2) for 24 hours (n=5 per treatment group). Cells
were then re-oxygenated for 18 hours in conditions identical to control cells and
mitochondrial membrane potential was assessed via flow cytometry using JC-1 staining,
which emits green fluorescence in monomer form, but emits red fluorescence when
aggregated in polarized mitochondria. (A) Representative FACS plots of JC-1 staining in
cells exposed to H/R injury. (B) Ratio of Red (+):Green (+) cells in each treatment group.
Higher values indicate more cells with polarized (healthy) mitochondria. Bars indicate
mean ± SEM. ****p<0.0001.

124

A

B

125

Figure 4.8. AP39 improves renal allograft function and survival and reduces renal
injury following 24-hour cold organ storage and allogeneic renal transplantation.
Survival rates (A) and serum creatinine levels (B) of renal transplant recipient Lewis rats
receiving donor Lewis kidneys perfused and stored in University of Wisconsin (UW)
solution only (UW; n=5) or UW solution plus 200 nM of the mitochondrial-targeted H2S
donor AP39 (AP39; n=3) for 24 hours at 4°C as well as sham-operated Lewis rats (Sham;
n=4). Lines indicate mean serum creatinine. (C) Acute tubular necrosis (ATN) scores of
renal grafts at time of sacrifice. Renal sections were stained with hematoxylin & eosin
(H&E) and assigned an acute tubular necrosis (ATN) score by a blinded transplant
pathologist (ATN scores out of 5; 0 = 0% graft ATN, 1 = <10% graft ATN, 2 = 11-25%
graft ATN, 3 = 26-45% graft ATN, 4 = 46-75% graft ATN, 5 = >75% graft ATN). Lines
indicate median ATN score. *p<0.05, **p<0.01.
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4.5 Discussion
Evidence for the therapeutic potential of H2S in treating pathologies of most major organ
systems is continually expanding 30. A number of prior studies have shown that H2S
treatment effectively protects kidneys exposed to warm ischemic injury, however the
effect of H2S during cold IRI has not been as well explored 17-20. We have previously
demonstrated that addition of H2S to standard organ preservation solution can mitigate
renal graft injury associated with prolonged cold storage during syngeneic RTx and
moderate cold storage during allogeneic RTx 21,22. The current study investigates whether
H2S can confer renoprotection in the context of a more injurious and clinically relevant in
vivo model combining prolonged cold organ storage and increased graft inflammation
associated with allogeneic RTx. As well, this study identifies mitochondria as an
important site of action during H2S-mediated protection against cold renal IRI and that
targeting H2S release to mitochondria during hypoxic/ischemic injury drastically
improves the potency of its protective effects in vitro and in vivo.
Our findings show that treatment of donor kidneys with H2S during prolonged cold
storage significantly improved resultant allograft function and survival compared to
kidneys stored in UW solution alone. These functional data were corroborated by
histological findings. Staining of donor kidneys with EthD-1 immediately following cold
storage showed that H2S treatment significantly blunted the progression of tissue necrosis
during prolonged cold storage compared to untreated kidneys. Allografts treated with H2S
also showed markedly decreased levels of apoptosis acutely following RTx compared to
UW treated allografts. These findings indicate that H2S limits renal cellular injury
associated with prolonged cold ischemia time, resulting in greater preservation of
functioning renal parenchyma following cold storage and improved recovery of allograft
function during the acute post-transplant period. The current study is the first to show that
H2S can protect donor kidneys during cold storage in a model that combines prolonged
cold ischemia time with allogeneic RTx to more closely resemble clinical situations.
Despite the early protective effects of H2S treatment in our model, only one H2S treated
animal survived until end of time course. Scoring of renal sections using criteria for acute
rejection from the Banff 97 working classification of renal allograft pathology indicated
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that graft loss from POD 6-14 was likely due to acute rejection. However, this is not
surprising as Brown Norway to Lewis RTx is known to illicit a robust acute rejection
response in the absence of immune suppression 31 and we have previously shown that
treatment of donor kidneys with H2S during cold storage does not significantly alter the
progression of allograft rejection in this model 22. However, it is notable that while acute
rejection normally occurred on POD 6-10 in our current and previous models of
allogeneic RTX, one H2S treated animal in each study avoided graft rejection until the
end of the time course. This observation suggests that, in a limited number of cases, H2S
treatment could potentially decrease the immunogenicity of donor kidneys following cold
storage and delay recognition of donor tissue antigens by the recipient immune system. In
any case, it is expected that combination of H2S treatment (during cold storage) with
immune suppressive therapy (following RTx) would result in significantly improved
long-term allograft function and survival rates compared to untreated kidneys. In
addition, considering that 24h represents an extreme period of cold storage in murine
RTx models, it is possible that addition of H2S to standard organ preservation solution
could extend maximum acceptable cold ischemia times and expand organ sharing
networks to optimize tissue type matching of donor organs to recipients.
Due to the relatively small number of studies investigating H2S-mediated renoprotection
during cold IRI, little is known regarding the specific cellular actions of H2S in this
context. Therefore, the second aim of our study was to identify a potential cellular
mechanism through which H2S can protect renal epithelial cells during cold renal IRI. It
has recently been suggested that mitochondria are a primary site of H2S activity. While
H2S exerts toxic effects at high concentrations through inhibition of cytochrome c in the
ETC, it has been conversely shown to stimulate ATP production at lower concentrations
by donating electrons to the ETC between complexes II and III via the enzyme
sulfide:quinone oxidoreductase (SQR) 32. This observation has led to the classification of
sulfide as the first known inorganic electron donor in mammalian cells 33. The idea that
specific mitochondrial actions are an important contributor to H2S-mediated
cytoprotection has been substantiated by the observation of several studies that H2S
treatment preserves mitochondrial membrane integrity and function during cellular injury
23,24,34

. It has also been shown that the cytosolic H2S-producing enzyme, CSE, can
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translocate to mitochondria during cellular injury, presumably to produce H2S where it is
needed most to mediate cellular stress responses 25. These perceived mitochondrial
actions of H2S have stimulated the notion that targeting H2S release to mitochondria may
improve the potency H2S-mediated protection during cellular injury.
To investigate whether mitochondrial effects of H2S are important to mediating its
protective effects during cold renal IRI, we treated renal epithelial cells with either the
non-specific H2S donor, GYY4137, or the mitochondrial-targeted H2S donor, AP39, and
exposed them to a physiologically relevant in vitro model of cold H/R injury. While
GYY4137 and AP39 are both synthetic donors that release H2S in a controlled manner
similar to physiological production, AP39 contains a cationic triphenylphosphonium
(TPP+) group that allows the compound to home to mitochondria before releasing H2S
28,35

. Our experiments showed that treatment with AP39 at nM levels drastically

improved cellular viability following cold H/R injury compared to untreated cells, while
GYY4137 was unable to protect cells at nM levels. Only at µM levels was GYY4137
able to confer protection against cold H/R injury, though it was not as effective as AP39
even at 1000-fold increased concentrations. As well, AP39 at nM levels significantly
reduced ROS production and preserved mitochondrial membrane integrity following cold
H/R injury compared both nM and µM levels of GYY4137. This study is the first to
investigate the potential protective effects of H2S using a physiologically relevant in vitro
model of cold H/R injury rather than artificially simulating warm ischemic injury via
chemical induction of hypoxia-inducible factor 1 (HIF-1), ETC inhibition or oxidative
stress. Our findings indicate that targeting of H2S release to mitochondria improves its
cytoprotective potency during cold H/R injury by >1000-fold and that the mitochondrial
actions of H2S may be sufficient confer renoprotection against ischemic injury. We also
show that treatment of donor kidneys with AP39 at a similar concentration during
prolonged cold storage significantly improves graft function and survival compared to
UW alone. This observation demonstrates that AP39 is effective against cold IRI in vivo
and again confirms the increased potency of mitochondrial-targeted H2S release as our
previous RTx models required use of ~1000-fold higher concentrations of the nonspecific sulfide salt, NaHS, to achieve a similar protective benefit during prolonged cold
storage 21,22.
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There are a number of potential explanations as to which mitochondrial processes are
influenced by H2S during cold IRI. As previously described, low levels of H2S can
stimulate ATP production through donation of electrons to the ETC 32. In the absence of
O2 and nutrients during ischemia, this action of H2S could potentially minimize the
detrimental impact of ATP depletion on cellular function and viability. Two recent
studies by the same research group have shown that nM levels of AP39 can stimulate
mitochondrial respiration and ATP production and are cytoprotective against oxidative
injury in both endothelial and renal epithelial cells 36,37. The authors also showed that
treatment of rats with AP39 during warm bilateral renal ischemia improved renal function
and decreased oxidative stress and inflammation following reperfusion 37. These studies
establish that stimulation of mitochondrial bioenergetics could be a viable protective
mechanism through of H2S during cellular injury. However, another possibility is that
H2S modulates mitochondrial ion channels during ischemic injury. It is well known that
H2S can both activate and inhibit ion channel activity through S-sulfhydration of various
ion channel subunits, including KATP channels, T-type and L-type Ca2+ channels and Clchannels 38. Considering the importance of mitochondrial Ca2+ influx and subsequent
mitochondrial swelling in the pathogenesis of IRI, a potential mitochondrial mechanism
of H2S-mediated protection is to either stimulate mitochondrial Ca2+ channels to pump
out incoming Ca2+ ions or inhibit mitochondrial Ca2+ channel activity to prevent initial
Ca2+ influx. One recent study has shown that treatment of rats with AP39 can inhibit Ttype Ca2+ channel activity on myocardial cell membranes 39, which could provide the
basis for a similar effect on mitochondrial Ca2+ channels in our model. Another potential
mitochondria-specific protective mechanism of H2S could be its anti-oxidant capacity. As
previously described, mitochondria are large producers of ROS during reperfusion due to
malfunctioning ETC complexes and xanthine oxidase activity. Since H2S is known to
directly inhibit reactive species in its HS- form 40 as well as upregulate levels of the
general anti-oxidant, glutathione 24, targeting H2S release to mitochondria could dampen
ROS activity at a critical centre of generation during ischemic injury. While some or all
of these potential mechanisms could be at play in our model, future experiments remain
to be completed to identify the specific mitochondrial effects of H2S during cold renal
IRI.
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In conclusion, treatment of donor kidneys with H2S mitigated ATN and apoptosis
associated with prolonged cold storage and improved allograft function and survival in
the acute phase following allogeneic RTx. Targeting of H2S release to mitochondria
improved the potency of H2S-mediated protection in both a physiologically relevant in
vitro model of cold renal H/R injury and an in vivo model of prolonged cold storage and
syngeneic RTx. Our findings are the first to show that H2S protects donor kidneys against
prolonged cold IRI during allogeneic RTx and that targeting of H2S release to
mitochondria improves the potency of these protective effects. Our findings provide a
strong base of evidence to support the notion that treatment of donor kidneys with H2S
could represent a novel, cost-effective strategy to minimize the deleterious impact of
prolonged cold IRI during RTx and ultimately improve clinical outcomes for renal
transplant patients.
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Chapter 5

5

Discussion

Overview: This concluding chapter summarizes the primary findings of the previous
studies and contextualizes their importance in the growing field of hydrogen sulfide
therapeutic research. Potential mechanisms of action for hydrogen sulfide during IRI and
possible future experiments aimed at characterizing these mechanisms as well as
translating hydrogen sulfide treatment to clinical practice of transplantation are also
discussed.
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5.1 Renal graft injury associated with cold organ storage
can be mitigated with hydrogen sulfide treatment
Our main goal of study has been to establish whether supplementation of standard organ
preservation solution with H2S can improve preservation of donor kidneys by mitigating
the detrimental effect of prolonged cold IRI on donor tissue. We have focused on this
initiative in order to aid in addressing the most pressing need in renal transplantation,
chronic shortage of available donor organs. Due to the short supply of this resource it is
imperative to make the best use of available donor kidneys, which entails limiting IRI
during transplantation to a degree that does not inflict any residual detrimental effects on
consequent graft function and survival. However, since organ preservation techniques
have only marginally improved in >30 years and increasing cold ischemia time remains
an indicator of DGF and worse graft function and survival, particularly in “marginal”
donor organs, we sought to explore innovative therapeutic strategies to optimize current
methods of organ preservation. We estimated that addition of a novel cytoprotective
molecule to standard organ preservation solution held the greatest potential of any
strategy to immediately improve clinical practice of organ preservation. This is because
treating only the donor organ with a short half-life molecule avoids secondary exposure
to donors and recipients and would limit unwanted side-effects and potential
infringement on current transplant protocols. We also reasoned that improving standard
organ preservation methods could possibly extend maximum acceptable cold storage
times and create a new reservoir of available donor organs by allowing use of kidneys
that would previously have been discarded due to prolonged cold ischemia. At the outset
of our investigation, we identified the family of molecules called gasotransmitters,
including NO, CO and H2S, as promising novel therapeutic molecules that are capable of
limiting IRI by exerting anti-inflammatory, anti-oxidant and anti-apoptotic effects in
response to tissue ischemic injury. We focused our efforts on examining the therapeutic
potential of H2S as it was the most recently characterized gasotransmitter and research
investigating its protective effects against cold renal IRI during transplantation was
scarce.
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Prior to our work only one study had shown that H2S can protect renal tissue during cold
storage, however this porcine model only measured hemodynamic parameters of renal
function following artificial organ reperfusion and did not involve actual transplantation
of the donor kidney 1. Therefore, to determine whether H2S treatment represents a viable
clinical option to prevent renal graft injury associated with prolonged cold storage, we
designed our studies to resemble actual clinical situations as closely as possible. Through
our experiments we have demonstrated that H2S is an effective cytoprotective molecule
against cold renal IRI and addition of H2S to standard organ preservation solution greatly
reduces the detrimental effects of cold organ storage on resultant graft function and
survival. We have shown that H2S provides a protective benefit in clinically relevant
models of both syngeneic and allogeneic murine RTx involving both moderate (6-hour)
and prolonged (24-hour) periods of cold storage, indicating that H2S is effective at
mitigating degrees of renal graft injury ranging from ordinary to extreme. In our studies,
donor kidneys receiving H2S during cold storage experienced quicker recovery of renal
function following RTx and greatly improved early survival compared to storage in UW
solution alone. Kidneys treated with H2S experienced markedly reduced ATN and
decreased acute expression of renal biomarkers of injury such as Kim-1 and Ngal,
indicating that H2S preserves renal function by preventing nephronic cellular injury
caused by loss of O2 and ATP during cold organ storage. These findings provide strong
evidence that application of H2S could improve the efficacy of standard cold organ
preservation protocols and reduce the deleterious impact of prolonged cold IRI on shortand long-term graft function and survival.
While current standard practice of organ preservation remains hypothermic storage of
organs in the peri-transplant period with or without use of PP, there has been much recent
support for the notion that normothermic preservation could provide superior protection
of organ function 2. Normothermic preservation methods were originally developed at the
outset of clinical organ transplantation in the mid-20th century but were abandoned due to
high cost and complexity of perfusion machinery 3. However, recent technological
advances have improved the feasibility of this preservation technique 2. While
hypothermic organ preservation aims to reduce the impact of ATP loss by reducing tissue
metabolic rates, normothermic preservation utilizes the opposite strategy of maintaining
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tissue metabolism under physiological conditions during the peri-transplant period. The
disadvantage of cold organ preservation is that suppressing cellular metabolism under
hypothermic temperatures only prolongs a finite period until tissue ATP levels fall below
the threshold needed to maintain cellular viability, resulting in tissue injury. In contrast,
preserving organs in a normothermic, physiological environment would theoretically
result in minimal ATP loss and could maintain cellular viability indefinitely, avoiding
induction of IRI and potentially increasing available time for tissue type matching 2.
However, while normothermic preservation has been successfully used to preserve donor
lungs 4, and is beginning to be utilized in clinical liver 5 and kidney 6 transplantation, it
remains a technologically complex and expensive procedure requiring complicated
perfusion solutions and large clinical teams to operate perfusion machinery. We chose to
focus our experiments on optimizing current standard cold organ preservation protocols
as we predicted this to be the most likely path to improving clinical practice in the short
term. As well, if current organ preservation protocols can be improved to a point that
prolonged cold ischemia time is no longer detrimental to clinical outcomes, this may
eliminate the need to develop more complicated and expensive methods such as
normothermic preservation. Alternatively, considering the abundance of evidence we and
others have contributed showing that H2S is also cytoprotective against warm renal IRI in
vivo 7-11, it is also possible that H2S could play a cytoprotective role during normothermic
preservation, potentially limiting the need for complicated preservation solutions to carry
oxygen to donor tissue. In any case, the therapeutic potential H2S of limiting renal IRI in
clinical situations using either or both hypothermic and normothermic organ preservation
continues to expand and could represent a key advance in improving future organ
preservation protocols.

5.2 Hydrogen sulfide can prevent initiation of downstream
renal injury pathways and promote tissue regeneration
An important insight in clinical organ transplantation is that acute tissue injury incurred
during transplantation procedures can initiate cellular and systemic pathological
pathways that cause chronic injury to accumulate in grafts and severely shorten the
lifespan of donor organs 12. Tissue inflammation and apoptosis are two important
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interrelated pathways in the pathogenesis of renal IRI during transplantation.
Inflammation is initiated upon reperfusion due to release of pro-inflammatory cytokines
such as interleukin (IL) 1, IL-6 and TNF-α, chemokines such as IL-8 and monocyte
chemoattractant protein 1 (MCP-1) and damage-associated molecular patterns (DAMPs)
such as the nuclear protein, high mobility group 1 (HMGB1), from injured and necrotic
tubular cells followed by expression of adhesion factors such as intercellular adhesion
molecule 1 (ICAM-1) and vascular cell adhesion molecule 1 (VCAM-1) on renal
vascular endothelium 13,14. Circulating polymorphonuclear (PMN) and monocytic innate
immune cells, responding to chemotactic signals from injured tissue, then infiltrate renal
parenchyma and release bursts of ROS and proteases that further damage renal tissue 15.
At the same time as inflammation is developing, renal parenchymal cells are also
undergoing apoptosis in response to prior ischemic injury. Apoptosis is an
immunologically “quieter” form of cell death compared to necrosis as potentially
immunogenic cellular components are broken down and packaged for phagocytosis in
membrane blebs, removing them from immune surveillance 16. There are two main forms
of apoptosis associated with IRI: extrinsic and intrinsic. Extrinsic apoptosis is activated
by binding of extracellular factors, such as FasL and TNF-α, to membrane receptors and
signals through caspase-8 to activate caspase-3. Initiation of intrinsic apoptosis is
independent of membrane receptor signaling but relies on release of cytochrome c and
apoptosis-activating factor 1 (Apaf-1) from injured mitochondria to activate caspase-9
and ultimately caspase-3. Caspase-3 is a central proteolytic enzyme activated through
both extrinsic and intrinsic apoptosis pathways and is a major effector of apoptotic
degradation of cellular components 16.
Both inflammation and apoptosis contribute to loss of renal graft function during and
after cold IRI. In addition to injuring renal parenchyma through release of ROS and
proteases, TNF-α production by infiltrating immune cells can cause cell death by
initiating extrinsic apoptotic pathways in renal tubular cells 16. Once undergoing
apoptotic cell death, renal proximal tubular cells express factors on cell membranes, such
as phosphatidylserine (PS), that mark them for clearance by phagocytic cells. While
proximal tubular cells have the capacity to phagocytose other apoptotic tubular cells
through interactions between membrane-bound Kim-1 and PS on the surface of
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neighbouring cells 17, high levels of tissue apoptosis require removal by peripheral
phagocytic immune cells, including macrophages 18. Uptake of apoptotic cells is
generally associated with polarization of macrophages to an M2 phenotype that is antiinflammatory and promotes tissue remodeling and repair, however continual activation of
this macrophage phenotype is known to be associated with propagation of chronic renal
fibrosis 18. While clinical immunosuppressive regimes target adaptive immune responses
against donor antigens, innate immune responses to donor organs largely remain
unaltered and chronic infiltration of innate immune cells, particularly macrophages, can
occur in renal grafts 19,20. Persistent renal graft inflammation and subsequent induction
and clearance of apoptotic parenchymal cells results in accumulation of macrophagederived pro-fibrotic compounds, most prominently transforming growth factor β (TGFβ), that promote proliferation of fibroblasts and consequent fibrogenesis 21. Since the
most common histological findings associated with long-term renal graft loss are tubular
atrophy with chronic interstitial fibrosis, preventing induction of antecedent inflammatory
and apoptotic pathways acutely following cold renal IRI could prove crucial to improving
long-term graft function and survival 22.
In our experiments, treatment of donor kidneys with H2S during cold organ storage was
invariably associated with decreased renal graft apoptosis compared to UW alone in the
early time period following RTx. This effect was seen in both syngeneic and allogeneic
RTx and following both moderate and prolonged cold storage. In addition, expression
levels of Olr-1, a molecule involved in extrinsic apoptotic signaling, and Timp-1, an
inhibitor of apoptotic pathway signaling, were both decreased in H2S allografts following
moderate cold storage compared to UW alone. These observations suggests a decrease in
overall magnitude of apoptotic signaling in H2S treated renal grafts, indicating that H2S is
preventing primary cellular injury associated with IRI and blunting induction of
downstream apoptotic pathways. It has been previously noted that H2S can inhibit
apoptotic signaling through direct S-sulfhydration of the p65 subunit of NF-κB,
promoting binding to ribosomal protein S3, which then amplifies nuclear p65 signaling
23

. While this phenomenon was not assayed in our study, it could provide a potential

explanation for decreased apoptotic signaling in H2S treated kidneys.
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The effects of H2S treatment on renal graft inflammation following cold IRI were not as
uniform as its effects on apoptotic signaling. Following syngeneic RTx, H2S treated
grafts experienced decreased acute infiltration of both MPO (+) neutrophils and CD68
(+) macrophages, as well as decreased mRNA expression of the pro-inflammatory
markers IFN-γ and ICAM-1. In contrast, H2S and UW treated allografts exhibited
similarly elevated levels of acute innate immune cell infiltration following both moderate
and prolonged cold storage and allogeneic RTx, with H2S treated kidneys possibly
showing increased macrophage infiltration compared to UW (data not shown). It is
unclear why H2S treatment did not reduce immune cell infiltration during allogeneic
RTx, but it is possible that Brown Norway to Lewis RTx involves a recipient immune
response too robust to be appreciably altered by H2S treatment during cold storage 24.
General clinical practice is to match donor and recipient human leukocyte antigens
(HLA) as closely as possible to avoid such a strong acute rejection episode. In such a
case involving more mild acute immune responses, H2S treatment could potentially
decrease innate immune infiltration similar to that seen during syngeneic RTx. Another
possibility is that, since only expression of CD68 was assessed and subtypes of
infiltrating macrophages were not able to be determined, elevated numbers of
macrophages present in H2S treated allografts could be populated by anti-inflammatory
Mϕ or pro-wound healing M2 macrophages rather than classical pro-inflammatory M1
macrophages. This notion may be supported by the fact that H2S treated allografts
exhibited decreased mRNA expression of SerpinA3 and Adamts1, two proteases involved
in the cellular response to inflammation, and conversely the most highly upregulated
genes associated with H2S were those involved in cellular proliferation and repair. These
observations indicate that H2S treatment during cold storage promotes early induction of
tissue regenerative pathways, which could be influenced by the actions of infiltration
anti-inflammatory/regenerative macrophages as opposed to pro-inflammatory
macrophages.
Another unexpected observation from our gene array study was that the second-most
highly upregulate set of genes in H2S treated allografts were those involved in cellular
response to IFN-γ signaling. Again, this result seems counterintuitive considering that
H2S treatment decreased expression of IFN-γ mRNA during syngeneic RTx. However,
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while IFN-γ is pro-inflammatory very early in the post-transplant period, it has been
shown to confer resistance to cellular necrosis and be essential for tolerance of allografts
later in the transplant curriculum 25-27. Thus, induction of IFN-γ signaling may represent a
previously unexplored pathways through which H2S could potentially limit immunemediated tissue necrosis and mediate acceptance of donor organs by the recipient
immune system. Despite its prevention of acute graft injury associated with cold IRI and
preservation of early graft function and survival, in the absence of adjunct immune
suppressive therapy H2S could not prevent donor kidneys from being rejected between
POD 6 and 10, regardless of cold storage time. It should be noted that one H2S animal in
each allogeneic RTx study survived until the end of the time course (POD 14), suggesting
that in a small portion of animals H2S could be preventing enough renal injury that
recognition of donor antigens by recipient immune cells is somewhat delayed. However,
many more animals would need to be transplanted to determine whether this is a true
effect of H2S treatment or a random phenomenon. While H2S did not prevent allograft
rejection, it is expected that its mitigation of early graft necrosis and apoptosis combined
with appropriate immunosuppression management would prevent initiation of fibrotic
pathways and translate to improved long-term function and survival compared to UW
alone. Thus, protection of human donor kidneys with H2S during cold storage could not
only reduce the detrimental impact of DGF on patient wellbeing and cost to healthcare
systems, but potentially delay induction of chronic injury processes and substantially
extend the life of donor organs.

5.3 Mitochondrial protection could be a key mechanism of
hydrogen sulfide-mediated renoprotection during cold
ischemic injury
The evidence supporting the protective actions of H2S against warm and cold renal IRI
continues to accumulate 28. While most studies, including our own, correlate H2Smediated protection with observational characterizations of various anti-inflammatory,
anti-oxidant and anti-apoptotic effects, unambiguously identifying specific cellular
mechanisms through which H2S operates during ischemic injury has remained elusive.
This is largely due to the nature of H2S as a volatile gas that can freely pass through lipid
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membranes 29. As such, H2S requires no membrane receptor to gain entry to cells and can
theoretically exert effects in virtually any cellular compartment. Possessing two
unbonded electron pairs, H2S is oxidized rapidly by cellular components and can
modulate protein activity through S-sulfhydration of thiol groups, such as those present
on ion channel subunits, including KATP channels, or on signaling molecules, such as NFκB 23,30. H2S can also indirectly enhance cGMP signaling through inhibition of
phosphodiesterases, react with metal centres to modulate activity of various
metalloproteins and exert anti-oxidant effects directly through inhibition of reactive
oxygen and nitrogen species or indirectly through induction of cellular glutathione 31,32.
Given these various and differing means H2S can use to modify cellular pathways along
with the promiscuity with which it can travel throughout the cell, characterizing one or
more specific mechanisms that mediate H2S protection against ischemic injury has
proven more problematic than originally thought.
One promising mechanistic pathway that has emerged from recent investigations on H2S
biology is the ability of H2S to directly maintain function of mitochondria and prevent
mitochondrial injury during ischemic episodes 33. It has long been known that, like other
gasotransmitters, high levels of H2S can exert cytotoxic effects via inhibition of
cytochrome c oxidase in the ETC 34. However, unlike NO and CO, H2S also appears to
play a physiological role in mitochondrial function during homeostasis 33. While its
homeostatic role is not well defined, this observation stems from the fact that H2S is
produced under normal physiological conditions from L-cysteine via the enzyme 3-MST
and from D-cysteine via the enzyme D-amino acid oxidase (DAO) specifically present in
mitochondria 35. The D-cysteine/DAO pathway is particularly prevalent in cerebellar and
renal tissue 35. Another major step in the recognition of the mitochondrial actions of H2S
was that in many models where H2S treatment protected against hypoxic or oxidative
injury, it was observed that H2S treated cells/tissues also exhibited increased
mitochondrial function and preservation of membrane integrity following cellular injury
36-39

. Subsequent studies also elucidated that during cellular injury including hypoxia,

CSE and CBS, which normally produce H2S in the cytosol, translocate to mitochondria
and produce high levels of H2S within the mitochondrial microenvironment 40,41.
Stemming from these common observations, the theory has been put forth that prevention
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of mitochondrial injury and preservation of cellular bioenergetics is a crucial aspect of
H2S-mediate protection against ischemic injury.
To test whether the actions of H2S on mitochondria are important for protection against
cold renal IRI during RTx in our studies, we utilized two novel, synthetic H2S donors,
GYY4137 and AP39. Both of these donors are able to independently penetrate cellular
lipid membranes and release H2S in a slow, controlled, physiological fashion, contrasting
with sulfide salts such as NaHS and Na2S, which release H2S in large bursts 42,43.
However, while AP39 contains an additional triphenylposphonium (TPP+) tail group that
facilitates its homing to negatively charged mitochondria prior to release of H2S, with
little accumulation in other subcellular organelles, GYY4137 lacks this TPP+ group and
releases H2S non-specifically upon entering cells 43-45. Using these two donors, we were
able to determine whether targeting of H2S release to mitochondria improves the potency
of its protective effects during cold renal IRI. Our study showed that AP39 treatment was
>1000-fold more potent at preventing renal epithelial cell apoptosis and necrosis during
cold H/R injury compared to GYY4137. AP39 treatment also resulted in decreased ROS
production and increased mitochondrial membrane integrity following cold H/R injury,
which was not seen with GYY4137 treatment. Treatment of renal grafts with AP39
during prolonged cold storage and subsequent syngeneic RTx improved renal graft
function and survival compared to UW alone. Animals treated with AP39 exhibited
similar survival levels by the end of the time course as animals treated with NaHS during
prolonged cold storage and syngeneic RTx, though AP39 concentrations were nearly
1000-fold less than NaHS concentrations. Our study is the first to show that targeting of
H2S release to mitochondria improves the potency of H2S-mediated protection against
cold hypoxic injury and treatment of renal grafts with AP39 during prolonged cold organ
storage can improve resultant renal graft outcomes. Considering the importance of
mitochondrial injury in promoting cell death pathways following ischemic insult, our
findings add to growing evidence that the mitochondrial actions of H2S could be essential
to mediating its protective effects during ischemic injury.
Targeting of H2S release to mitochondria is predicted to provide significant advantages in
clinical application of H2S treatment. Using an approach that targets delivery of
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therapeutic molecules directly to the site of action can eliminate potential unwanted side
effects of treatment. The protective effects of H2S can be context-specific and general,
systemic application of therapeutic doses of H2S could exacerbate some underlying
conditions while treating the primary illness. For instance, while H2S treatment is antiinflammatory during ischemic and oxidative injury, it has been shown to be proinflammatory in models of systemic inflammation such as septic shock and burn injury
46,47

. While an advantage of our treatment modality is that only donor organs are given

treatment instead of systemic treatment of donor and/or recipient, which limits
undesirable side-effects, targeted delivery of H2S becomes of much greater importance in
other disease or injury states that are only treatable by systemic application of H2S. In
addition, the increased potency of H2S protection when targeted to mitochondria could
allow the use of much smaller treatment doses to elicit beneficial effects of H2S with
negligible possibility of promoting detrimental secondary outcomes.

5.4 Future directions of study
Molecular mechanisms of hydrogen sulfide activity
Our studies have demonstrated that addition of H2S to standard organ preservation
solution prevents renal graft injury associated with prolonged IRI and improves resultant
renal graft function and survival compared to standard UW solution alone. H2S treatment
appeared to modulate the activity of downstream apoptotic, inflammatory and
proliferative pathways, while targeting of H2S to mitochondria drastically improved the
potency of its protective effects against hypoxic/ischemic injury. While we were unable
to determine the exact molecular mechanisms through which H2S modulates
mitochondrial pathways, there are a number of possibilities based on previous literature.
Other than cytochrome c oxidase inhibition, the most well studied mitochondrial action
of H2S is the donation of electrons at low concentrations to stimulate ATP production in
the absence of oxygen 48. It is postulated that maintenance of cellular bioenergetics
through low level stimulation of ATP production can prevent activation of cellular injury
pathways resulting from ATP loss during ischemia. Future studies should involve
assessment of mitochondrial metabolism and respiration during cold H/R injury to more
closely investigate whether mitochondrial targeting of H2S can promote preserve cellular
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metabolism during cold hypoxic injury. It has been previously demonstrated that H2S
exerts some cellular effects through alterations in the activity of various calcium ion
channels 49. Indeed AP39 was recently shown to inhibit calcium channels present on
myocardial cell membranes 50. Therefore it is also possible that by modulating the
activity of calcium ion transporters to prevent Ca2+ influx and subsequent mitochondrial
swelling, H2S can prevent release of cytochrome c and activation of intrinsic apoptotic
pathways during reperfusion. Future in vitro experiments using inhibitors of
mitochondrial-specific calcium channels should investigate whether H2S treatment can
prevent mitochondrial calcium influx during cold H/R injury. In addition, investigations
assessing activity of key effectors of this pathway such as anti-apoptotic molecule Bcl-2
and pro-apoptotic molecules cytochrome c, Bax and caspase-9 during cold H/R injury
should elucidate whether H2S treatment can halt cellular apoptosis through modulation of
this intrinsic apoptotic pathway. A third possibility is that the mitochondrial targeting
could place H2S in the optimal position to directly inhibit excessive levels of ROS
produced by dysfunctional mitochondria during reperfusion. Experiments designed to
assess this possibility could include use of real-time fluorescent microscopy in
conjunction with non-specific H2S donors and glutathione inhibitors to spatially visualize
whether targeting of H2S release to mitochondria reduces mitochondrial ROS production.
These proposed mechanisms of H2S-mediated protection of mitochondria during renal
IRI are depicted in Figure 5.1.
Another potential protective mechanism of H2S could be through modulation of cellular
regulated necrosis pathways. Regulated necrosis pathways are a distinct set of cell death
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Figure 5.1. Proposed mechanisms of H2S-mediated protection of mitochondria
during cold renal IRI.
During ischemia, ATP depletion causes inhibition of mitochondrial Na+/K+ ion channels,
resulting in decreased mitochondrial membrane potential (Ψm), influx of Ca2+ ions and
subsequent swelling of mitochondria. Prolonged periods of ischemia can permanently
damage complexes in the electron transport chain (ETC), which produce a burst of ROS
as oxygen floods cells upon reperfusion. Reactive oxygen species are also produced in
mitochondria by conversion of xanthine dehydrogenase to xanthine oxidase during
ischemia. Xanthine oxidase converts hypoxanthine to uric acid, producing superoxide as
a byproduct. High levels of mitochondrial ROS production combined with Ca2+-induced
mitochondrial swelling result in severe damage of mitochondrial membranes and
formation of mitochondrial permeability transition pores (MPTP), releasing pro-apoptotic
factors, cytochrome c and apoptosis inducing factor 1 (Apaf-1), which then activate the
caspase 9/3 apoptotic signaling cascade, initiating cellular apoptosis. ROS-mediated
mitochondrial damage also results in activation of pro-inflammatory NF-κB signaling and
ultimately innate immune cell recruitment. H2S is proposed to mitigate the following
pathophysiological mitochondrial mechanisms during IRI: i) Prevent loss of Ψm and
subsequent Ca2+ influx through stimulation of ATP production via donation of electrons
to the ETC and modulation of Ca2+ channel activity; (ii) Inhibit ROS production through
direct inhibition (in HS- form) and upregulation of the anti-oxidant glutathione; (iii)
Modulate pro-inflammatory NF-κB signaling via S-sulfhydration of the p65 subunit.
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pathways that exhibit some features of both apoptotic and necrotic cell death in that they
are regulated by cellular signaling pathways in response to extracellular stimuli (similar
to apoptosis) but still result in leakage of cellular components into the interstitium and
subsequent inflammation (similar to necrosis) 51. There are numerous cell death pathways
exhibiting varying aspects of cell death processes that have now been classified as
regulated necrosis pathways, including necroptosis, pyroptosis, ferroptosis, parthanatos,
ETosis, NETosis, pyronecrosis and oxytosis 51. Necroptosis is the most fully
characterized regulated necrosis pathway and has been shown to be a contributor to the
pathogenesis of renal IRI 51,52. This pathway is similar to apoptotic pathways in that it is
typically initiated through binding of cellular receptors by pro-inflammatory extracellular
signaling molecules, such as TNF-α and Fas 53,54. However, necroptosis diverges from
apoptosis pathways when caspase 8 activity is inhibited, which allows activation of
receptor-interacting protein kinase 1 and 3 (RIPK1 and RIPK3) signaling leading to
destruction of cellular membranes and release of cytoplasmic contents 55-58. This model is
supported by the observation that a class of molecules called necrostatins can inhibit
necroptotic pathways through inhibition of RIPK signaling activity 55,59. It has been
suggested that mitochondrial injury is an important first step in the degradation of cellular
membranes caused by necroptosis. This notion is due to the observation that
conglomerates of RIPK1 and 3 molecules along with other secondary signaling
molecules (termed the necrosome) translocates across mitochondrial membranes early in
necroptotic cell degradation, which appears to cause Ca2+ influx and ROS-mediated
mitochondrial injury 60-62. Considering the mitochondrial protective effects of H2S, it is
possible that H2S could disrupt these mitochondria-associated necroptotic signaling
pathways. Only one previous study has attempted to investigate the potential regulatory
actions of H2S on necroptotic signaling. This report demonstrated that treatment of a
neuronal cell line with an H2S-releasing derivative of acetylsalicylic acid curbs oxidative
damage resulting from a necrostatin-sensitive cell death pathway induced by glutamate
treatment compared to acetylsalicylic acid alone 63. While the authors did not assess the
actions of H2S on specific necroptosis signaling molecules, the protective effects of H2S
in this model were also predictably associated with upregulation of glutathione, Bcl-2 and
HO-1 63. Thus, it is possible that the mitochondrial effects of H2S could represent a novel
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therapeutic strategy to restrict necroptosis and potentially other regulated necrosis
pathways and diminish the detrimental impact of this inflammatory form of cell death
during renal IRI.
One aspect of renal recovery and DGF that was not specifically assessed in our studies is
the disruption of renal blood flow following cold renal IRI and development of renal
resistance during organ reperfusion. Throughout the ischemic period, decreasing ATP
levels result in dysfunction of renal microvascular endothelial cells and vasoconstriction
of microvessels along with congestion of peritubular capillaries via accumulation of
blood cells and activation of coagulation cascades by damaged endothelium 64. These
events result in drastically reduced renal blood flow (RBF) and increased renal resistive
index (RI) of donor organs 64. Upon reperfusion, renal grafts that exhibit increased RI are
not immediately able to distribute blood the whole graft, resulting in some portions of the
donor organ receiving blood and others experiencing varying periods of damaging warm
ischemia. As such, previous studies have shown that renal grafts that exhibit increased
RBF experience decreased rates of DGF, while grafts characterized by elevated renal RI,
particularly DCD kidneys, are more likely to experience DGF and have increased risk of
graft loss 5 years post-transplant 65-68. It is highly possible that maintenance of RBF and
reduction of RI plays a role in the improvement of early graft function and survival
observed in renal grafts treated with H2S during cold storage. While it was not technically
feasible to quantify these parameters in our murine models of RTx, once blood supply
was reconnected gross observation showed that H2S treated kidneys tended to reperfuse
in a quicker and more uniform fashion compared to UW treated kidneys. Since H2S is
known to strongly potentiate vasodilation through activation of KATP channels on smooth
muscle cells 69, it is probable that H2S could act similarly on renal microvasculature to
maintain RBF following IRI. Supporting this notion, previous work from our laboratory
has shown that treatment of porcine kidneys with H2S during pulsatile perfusion
improved resultant parameters of RBF and renal RI 70. Interestingly, we also found that
renal allografts treated with only UW during 6h cold storage exhibited increased mRNA
expression of a number of genes involved in coagulation pathways, indicating that H2S
could also influence RBF during reperfusion by preventing activation of the coagulation
cascade and averting renal microvascular congestion. Thus, while it was not directly
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investigated in our studies, modulation of renal graft hemodynamic parameters during
cold IRI could represent an important pathway in H2S-mediated improvement of early
renal graft function and should be more closely examined in future studies.
Application of hydrogen sulfide to ECD and DCD murine renal transplant models
While most research involving animal studies, including the present work, utilizes young,
healthy animals in their injury models, these demographics are generally not
representative of actual patient populations. In Canada, the average kidney donor age is
47.5 ± 13.2 years for living donors and 55 ± 12.6 years for deceased donors, with ECD
and DCD donors exhibiting additional co-morbidities and risk factors for decreased graft
function and survival 71. Since clinical outcomes are far superior for living donation and
more deceased donor organs are being utilized to combat organ shortages, future research
should focus on optimization of use deceased donor organs. These studies should involve
use of animals that better represent actual patient demographics, such as animals that are
older and/or exhibit risk factors for renal injury including such examples as Zucker
Diabetic Fatty (ZDF) rats and spontaneously hypertensive (SHR) rats. The potential for
H2S to improve transplant outcomes could prove to be greater in these situations since
these initially suboptimal donor kidneys would be more susceptible to experimental cold
IRI compared to optimal donor kidneys used in our previous experiments. In addition,
future investigations of renoprotective effects of H2S during transplantation should
involve the use of DCD models of renal transplantation, as this is currently the most
rapidly expanding donor organ population in North America and are associated with high
rates of DGF and worse long-term outcomes 72. One prior study has shown that H2S can
protect porcine kidneys against IRI in an experimental model that approximates DCD
transplantation, though without actual transplantation of kidneys into recipient animals 1.
Our laboratory has begun to develop a clinically relevant murine model of DCD RTx
involving periods of warm ischemia prior to cold storage and transplantation, with
promising results showing that H2S treatment during both phases of ischemia improves
consequent graft outcomes 73. Future studies expanding these findings of H2S treatment
during DCD RTx, possibly involving ECD-like donor animals, should aid in determining
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the extent to which H2S treatment can improve transplant outcomes in representative
clinical situations.
Translation to clinical practice
The ultimate goal of our research is to translate our experimental findings showing that
H2S improves preservation of donor kidneys into clinical situations in order to improve
clinical outcomes for renal transplant patients. Studies that demonstrate the safety and
efficacy of delivery of H2S to human donor kidney tissue should be pursued to help
expedite this process. Many donor kidneys, particularly those from “marginal” donors,
are discarded by physicians prior to transplantation due to combinations of factors such
as increased donor age, prolonged ischemic time, donor co-morbidities and cause of
death that will likely result in non-function of transplanted grafts 72. Impactful studies
could be designed that obtain discarded human donor kidneys and assess whether
preservation in solution supplemented with H2S could improve the health of these
kidneys to such a degree that they could be utilized for transplantation. Positive findings
results from a study such as this could have the potential to greatly expand the donor
organ pool and ease some of the strain on this scarce resource.
While use of synthetic H2S donors has shown promising results in reducing the
detrimental impact of tissue ischemia, another potential strategy to speed clinical
translational of H2S-based preservation techniques is to investigate the renoprotective
effects of H2S-releasing compounds derived from organic sources already approved for
treatment of unrelated conditions. Two such potential substances are thiosulfate and aged
garlic extract (AGE). Thiosulfate is a naturally occurring intermediate of sulfur
metabolism and is currently used as a part of treatment regimens for clinical conditions
ranging from calciphylaxis, a highly morbid necrotic skin disorder associated with
ESRD, to cyanide poisoning 74,75. However, thiosulfate has also recently been shown to
produce H2S under physiological conditions and mediate protection of neurons from
ischemic injury 76,77. Aged garlic extract is known to exert potent anti-oxidant effects and
has a wide variety of clinical applications, including reduction of blood pressure in
hypertensive patients and slowing the progression of atherosclerotic plaques 78-80.
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However, while the most well studied component of AGE is the anti-oxidant Sallylcysteine (SAC), it also contains polysulfide compounds diallyl-disulfide (DADS) and
diallyl-trisulfide (DATS) that have been shown to be sources of H2S production 81. A few
studies have shown that application of garlic and it H2S-producing derivatives can
mitigate injury associated with warm IRI, particularly in renal and myocardial tissue 82,83.
Given their ability to produce H2S and mitigate warm ischemic injury in a variety of
tissues, along with their current use as part of standard clinical treatments, these two
therapeutic substances appear to have considerable potential for improving clinical
preservation of donor kidneys. Future studies should aim to investigate the protective
effects of these and other readily translatable H2S donor molecules in the context of cold
renal IRI to determine their potential, and the potential of H2S in general, to improve
clinical outcomes of renal transplantation.
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